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SUMMARY 
Rectal cancers comprise 35% of all diagnosed colorectal cancers (CRC), being the third most 
common among gastrointestinal cancers. Despite the benefits of neoadjuvant 
chemoradiotherapy (CRT), 5-fluorouracil (5-FU)-based regimens plus radiotherapy (RT), 15-
20% of patients suffer from relapse. Pathological staging remains the most important 
prognostic factor in rectal cancer and the search for new prognostic and predictive 
biomarkers is fundamental. DNA damaging agents and ionizing radiation used in the therapy 
of human cancers may induce senescence of cancer cells. Senescent cells exhibit a secretory 
phenotype that can affect cancer cell behavior and, eventually, clinical prognosis. In this work 
we hypothesize that neoadjuvant CRT-induced cellular senescence may affect rectal cancer 
relapse. To experimentally test our hypothesis, we cultured colon cancer cells induced into 
senescence by exposure to 5-FU or doxorubicin. SAS-media were enriched in IL-8, TGF-α, 
VEGF, cystatin C, LCN2, MIF, EMMPRIN, and uPAR, and exerts a positive effect on the 
proliferation of cycling colon and rectal cancer cells. SAS-medium was capable of paracrine 
induction of epithelial-to-mesenchymal (EMT) transition in colon and rectal cancer cell lines, 
of increased cell invasion in vitro, and of increased chemosensitivity to 5-FU. Moreover, we 
found that in rectal cancer samples from patients treated with neoadjuvant CRT tumor cell 
niches enriched for senescent cells bookmark regions of increased expression of EMT-related 
genes (slug, snail, vimentin) when compared to nearby senescent-null control regions. We 
provide evidences that therapy-induced senescent cancer cells influence the tumor 
microenvironment by promoting EMT via short range interactions. Next, to relate 
neoadjuvant CRT-induced cellular senescence with rectal cancer relapse, we retrospectively 
studied rectal cancers from 35 patients treated with neoadjuvant therapy. Data showed no 
correlation between the senescence markers p16INK4a and p21WAF1 and relapse, and it was not 
possible to validate a method for senescence detection in formalin-fixed and paraffin-
embedded (FFPE) samples. Altogether, our findings showed that secretomes from senescent 
colon cancer cells may induce effects with opposite prognostic value. Prospective studies 
shall clarify whether, after neoadjuvant therapy, the presence of senescent cells add 
prognostic power on cancer recurrence and patient survival. 
Keywords: Therapy-induced cellular senescence; rectal cancer; neoadjuvant chemotherapy; 
senescence-associated secretory phenotype; 5-fluorouracil 
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RESUMO 
O cancro do reto representa cerca de 35% de todos os tumores colo-retais (CCR) diagnosticados, 
sendo o terceiro mais comum entre os tumores gastrointestinais. Apesar da melhoria significativa 
no contexto da terapia neoadjuvante, 5-fluorouracil (5-FU) em concomitância com radioterapia 
(RT), as taxas de recidiva permanecem elevadas, cerca de 15-20%. O estadiamento histo-
patológico permanece o principal fator de prognóstico sendo fundamental a pesquisa de novos 
biomarcadores de prognóstico. No tratamento da doença oncológica, a terapêutica com 
citostáticos e radiação pode induzir senescência cujo fenótipo secretor é conhecido por 
senescence-associated secretory phenotype (SASP), capaz de modificar o micro-ambiente e 
contribuir para a progressão tumoral. Este trabalho teve por base a hipótese de que a 
senescência celular induzida pela quimioterapia (QT) pode estar correlacionada com a recidiva 
em doentes com cancro do reto em estadio avançado. Para testar experimentalmente esta 
hipótese foi induzida senescência em células de cancro do cólon (HCT 116) por exposição ao 5-FU 
ou doxorrubicina. A análise dos meios condicionados obtidos (SAS-media) revelou a presença dos 
compostos IL-8, MIF, VEGF, uPAR, EMMPRIN, cistatina C, lipocalina-2 e TGF-α, que se verificou 
estimularem a proliferação de células de cancro do cólon e reto não senescentes. SAS-medium 
induziu também um aumento significativo da expressão de marcadores moleculares de transição 
epitélio-mesênquima (TEM), do potencial invasivo em células tumorais não senescentes, e da 
quimio-sensibilidade, o que sugere um duplo efeito nas células tumorais não senescentes. Em 
amostras humanas de tumores do reto verificamos um aumento da expressão de marcadores 
mesenquimais em zonas tumorais associadas à presença de células senescentes, constituindo 
uma forte evidência de que a senescência induzida pela QT influencia de facto o micro-ambiente 
tumoral, promovendo a TEM. Para determinar uma possível correlação entre a presença de 
células senescentes e a recidiva no cancro do reto, realizámos um estudo retrospetivo envolvendo 
35 amostras de doentes submetidos a terapia neoadjuvante. Os dados obtidos não permitiram 
estabelecer uma correlação entre os marcadores de senescência p16INK4a e p21WAF1 e a recidiva, 
não tendo sido possível validar um método que consideremos adequado para a identificação de 
células senescentes em amostras fixadas. Em conclusão, os dados obtidos neste trabalho sugerem 
que o secretoma de células epiteliais tumorais pode induzir fenómenos com valor prognóstico 
opostos. Estudos prospetivos futuros irão contribuir para clarificar o papel da senescência celular 
na definição de novos critérios de prognóstico e identificação de novos alvos terapêuticos. 
Palavras-chave: Senescência celular induzida pela terapia; cancro do reto; quimioterapia 
neoadjuvante; secretoma associado à senescência; 5-fluorouracil.  
XVI 
 
 
SCOPE OF THE THESIS 
This thesis is organized in four chapters. In Chapter 1 the background, significance, and 
aims of this study are presented. Rectal cancer epidemiology and clinical management; 
the mechanism of action of 5- fluorouracil; and the molecular basis and significance of 
cellular senescence, were reviewed according to the literature. Together, this review 
comprises the theoretical fundaments that support our hypothesis that therapy-induced 
cellular senescence can be related with rectal cancer relapse. In Chapters 2 and 3 are 
presented and discussed the results obtained during the course of this work (Illustration 
1). Chapter 2 refers to a manuscript submitted to Clinical & Experimental Metastasis 
(CLIN-S-14-00188, submitted on September 11, 2014), entitled “Therapy-induced cellular 
senescence has a dual effect in rectal cancer increasing invasiveness and 
chemosensitivity”, by Joana Tato-Costa, Sandra Casimiro, Teresa Pacheco, Ricardo Pires, 
Afonso Fernandes, Irina Alho, Pedro Pereira, Paulo Costa, Henrique Bicha Castelo, João 
Ferreira, and Luís Costa. Chapter 3 describes a clinicopathologic study conducted to 
elucidate if cellular senescence could be correlated with relapse in rectal cancer. Finally, 
in Chapter 4 it is presented a final discussion of the key findings from the previous 
chapters and of the potential translational relevance of senescence in the management of 
advanced rectal cancer. 
 
 
 
 
 
Disclaimer: I hereby declare that I majorly contributed for the conception and design, 
development of methodology, acquisition of data, analysis and interpretation of data and 
writing, review and/or revision of each group of results and chapters of this thesis.  
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Illustration 1- Conceptual framework used for the investigation of the effects of cellular senescence in rectal cancer. 
HCT 116; SW48 – colon cancer cell lines and SW837 - rectal cancer cell line, all acquired from ATCC; SAS-medium – 
culture medium enriched of the Senescence-Associated Secretome; EMT - Epithelial-Mesenchymal Transition; W/O – 
Without; W/ - With; CRT –Chemoradiotherapy; RT-qPCR - Semi-quantitative real-time PCR; β-gal - β-galactosidase; IF – 
Immunofluorescence; WB – Western blot; FFPE - Formalin-Fixed, Paraffin-Embedded; IHC – Immunohistochemistry. 
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1 GENERAL INTRODUCTION 
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1.1 Incidence and classification of colorectal cancer 
 
Colorectal cancer (CRC) is the third most common form of cancer worldwide. In 2012, 
according to the GLOBOCAN Project, sponsored by the International Agency for Research 
on Cancer (IARC) and World Health Organization (WHO), CRC represented 9.7% of the 
world's new cancers with 1.36 million new cases diagnosed [5].  
In Portugal, in the same period, 7 129 new cases were diagnosed with CRC, corresponding 
to 14.5% of all diagnosed cancers. Here, CRC was the second most common cancer 
affecting women (after breast cancer) and men (after prostate cancer), and had the 
highest mortality rate (15.7%) [5].  
Staging of the disease dictates the therapeutic strategies. According to international 
guidelines from the European Society for Medical Oncology (ESMO), the preoperative 
staging of CRC is based on the clinical and radiological evaluation of the tumor growth 
and distant spread [6, 7]. Following surgery, the pathologic TNM classification is based on 
the evaluation of size and extent of the primary tumor (ranging from T0 to T4), the 
presence of regional lymph nodes involvement (N0 to N2), and the existence of distant 
metastasis (M0 or M1) (Table 1.1) [8].  
CRC can occur at different locations within the colon or rectum. Rectal cancer is the third 
most common among gastrointestinal (GI) cancers, and represents approximately 35% of 
all CRC cancers [6]. Rectal cancers are located below 12 cm from the anal verge as 
measured with a rigid rectoscope, or below the pelvic promontory as visualized by X-ray, 
computed tomography, magnetic resonance imaging (MRI) or during surgery [7]. Colon 
and rectal cancers have several features in common and are epidemiologically gathered 
as CRC. However, the surgical and therapeutic management of colon and rectal cancers is 
different. This thesis and following chapters will focus on rectal cancer. 
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Table 1.1- TNM Classification system for colorectal cancers [8].  
TNM system   
T- Primary tumor  
Tx- Primary tumor cannot be assessed 
T0- No evidence of primary tumor 
Tis- Carcinoma in situ: intraepithelial or 
invasion of lamina propria 
T1- Tumor invades submucosa 
T2- Tumor invades muscularis propria 
T3- Tumor invades subserosa or into non-
peritonealized pericolic or perirectal tissue 
T4- Tumor directly invades other organs or 
structures and/or perforates visceral 
peritoneum 
 
  
  
  
  
  
 T4a- Tumor perforates visceral 
peritoneum 
T4b- Tumor directly invades other 
organs or structures 
 
N- Regional lymph 
nodes  
Nx- Regional lymph nodes cannot be 
assessed 
N0- No regional lymph nodes metastasis  
N1- Metastasis in 1-3 regional lymph nodes 
 
  
 N1a- Metastasis in 1 regional lymph 
node 
N1b- Metastasis in 2-3 regional lymph 
nodes 
N1c- Tumor deposit(s), i.e., macro or 
microscopic nests or nodules in the 
subserosa, or in non-peritonealized 
pericolic or perirectal soft tissue 
without regional lymph nodes 
metastasis 
  
  
  
 
 
N2- Metastasis in 4 or more regional lymph 
nodes 
N2a- Metastasis in 4-6 regional lymph 
nodes 
N2b- Metastasis in 7 or more regional 
lymph nodes   
M- Distant metastasis M0- No distant metastasis 
M1- Distant metastasis 
 
 M1a- Metastasis confined to 1 organ 
M1b- Metastasis in more than 1 organ 
or the peritoneum    
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1.2 Rectal Cancer  
1.2.1 Treatment of locally advanced primary rectal cancer 
The standard of care treatment for locally advanced rectal cancer (stage T3/T4 and/or N 
positive) comprises preoperative (neoadjuvant) chemoradiotherapy (CRT), followed by 
surgery and postoperative (adjuvant) chemotherapy (CT) (Figure 1.1).  
 
Figure 1.1- Representative scheme of current guidelines for the treatment of locally advanced rectal 
cancer. 
5-FU -5-fluorouracil; Leucovorin- Folinic acid; FOLFOX- Chemotherapy regimen comprising folinic acid 
(Leucovorin), 5- fluorouracil (5-FU) and oxaliplatin; RT- radiotherapy; cont. iv- continuous intravenous 
infusion. Adapted from [9]. 
 
New surgical techniques have substantially improved local-regional control and overall 
survival1 (OS), being total mesorectal excision the gold standard procedure, with local 
failure rates below 10% and better prevention of tumor cells spread at surgery [10]. 
                                                          
1 Overall survival (OS) - The length of time those patients are alive since either the date of diagnosis or the start of 
treatment for a disease. 
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However, and despite surgical and therapeutic advances, 15 to 20% of patients with 
locally advanced rectal cancer will suffer from local or distant relapse, mainly to the liver, 
lung and distant lymph nodes. In consequence, about one third of the diagnosed patients 
will die within 5 years after treatment [11]. 
In 2006, results from The European Organization for Research and Treatment of Cancer 
(EORTC) 22921 multicentre clinical trial, enrolling 1011 patients with primary T3/T4 rectal 
cancers, suggested that a pre-surgical treatment with radiotherapy (RT) combined with 
radiosensitive CT could significantly improve downsizing and downstaging of tumors and 
decrease local recurrence rates, when compared to RT alone (57.1% versus 42.4%) [11].  
Results from the National Surgical Adjuvant Breast and Bowel Project R-03 (NSABP R‑03) 
trial, comparing  the effects of neo plus adjuvant CRT in patients with locally advanced 
rectal adenocarcinoma, showed that the five year disease free survival2 (DFS) was 
significantly improved for patients treated with neo plus adjuvant therapy (65% versus 
53%, p = 0.011). In addition, the five year OS for patients treated with neo plus adjuvant 
therapy was significantly higher in comparison with patients with only post-operative 
therapy (75% versus 66%, p = 0.065) [12].  
Different studies have demonstrated that neoadjuvant CRT not only improves surgical 
outcomes, but also reduces tumor burden and RT-related toxicity, and increases 
radiosensitivity [13, 14].  
The advent of targeted therapy with target-specific monoclonal antibodies, namely 
cetuximab and bevacizumab, in combination with CT expanded the treatment options 
and further improved clinical outcomes. However, these improvements are so far only 
reported in cases of metastatic CRC [15].  
Cetuximab is a monoclonal antibody that binds to Epidermal Growth Factor Receptor 
(EGFR) and blocks ligand-induced phosphorylation of the downstream effectors of the 
pathway. The overexpression or up-regulation of EGFR is associated with poor survival in 
                                                          
2
 Disease-free survival (DFS) - the period of time after primary treatment in which the patient does not show any signs 
or symptoms of the disease. 
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CRC and occurs in 60 to 80 % of CRCs. Upon activation, EGFR activates an important 
signaling pathway that regulates cell differentiation, proliferation, migration, 
angiogenesis, and apoptosis, all of which become deregulated upon over expression of 
the receptor. A clinical trial where was compared the combination of cetuximab and 
irinotecan (the semi-synthetic topoisomerase I inhibitor camptothecin used as CT drug) 
with cetuximab in monotherapy in metastatic CRC cancer patients showed that the 
response rate in the combination-therapy group was significantly higher than that in the 
monotherapy group (22.9% vs. 10.8%, p=0.007). The median time to progression3 (TTP) 
was significantly improved in the first group (4.1 vs. 1.5 months, P<0.001) although 
without significant differences in median OS (8.6 versus 6.9 months, p=0.48). Cetuximab 
has proved to be clinically significant when given in combination with irinotecan in 
patients with metastatic disease [16]. 
Bevacizumab is a monoclonal antibody against Vascular Endothelial Growth Factor 
(VEGF), an important regulator of physiologic and pathologic angiogenesis. Bevacizumab 
has antiangiogenic effects and currently being evaluated in clinical trials as a treatment 
for several cancers. In a phase 3 clinical trial the addition of bevacizumab to a standard 
combination of three CT drugs (CT+bev) improved OS among patients with metastatic 
CRC when compared to CT plus placebo (CT+PBO) (20.3 versus 15.6 months, p<0.001). 
The median progression free survival4 (PFS) was 10.6 months vs. 6.2 months (p<0.001) 
and the corresponding rates of response were 44.8% vs. and 34.8% (p=0.004) [17]. 
1.2.2 Prognostic and predictive factors 
The major prognostic factors in rectal cancer are: clinical staging before surgery and 
pathologic tumor staging after surgery, including: the presence of residual tumor; the 
number of positive lymph nodes; and tumor differentiation grade. In addition, vascular 
and nodal invasion; the number of positive lymph nodes; perineural growth; and invasion 
of adjacent organs, are also important prognostic factors [18-20]. 
                                                          
3
 Time to progression (TTP) - the period of time from the date of diagnosis or the start of treatment for a disease until 
the progression of the disease. 
4
 Progression-free survival (PFS) - the period of time between treatment initiation and tumor progression or death from 
any cause.  
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The pathologic response assessed by the tumor regressing grade (TRG) after pre-
operative CRT, has also been considered a valuable tool to predict prognosis and long-
term survival [21]. This system is based on the determination of the amount of viable 
tumor cells versus fibrosis, ranging from TRG4 (when no viable tumor cells are detected) 
to TRG0 (when fibrosis is completely absent). Despite some evidences that indicate TRG 
as an independent prognostic factor and predictor for long-term outcome after 
preoperative treatment [22], only pathological staging (TNM) has been validated in multi-
institutional prospective studies and remains the main prognostic tool for rectal cancer. 
Mutational profiling of specific genes has also been reported as useful in predicting 
treatment response and survival in patients with metastatic CRC. Mutation(s) in K-ras, 
PIK3CA, and BRAF showed to be highly associated with treatment response to targeted 
therapy with monoclonal antibodies anti-EGFR as well as to the clinical outcome of the 
patients [23]. The most clinically relevant example relates with K-ras mutations and poor 
responses to EGFR monoclonal antibodies like cetuximab. In fact, patients with mutations 
in K-ras are unlikely to benefit from anti-EGFR therapy and are significantly associated 
with resistance to cetuximab (p< 0.001) and a lower OS (10.1 versus 14.3 months in 
patients without mutation; p = 0.026) [24]. 
1.3 5-fluorouracil (5-FU) 
1.3.1 Mechanism of action 
5-fluorouracil (5-FU) has been used for more than 40 years to treat cancer and is still 
recommended as a first-line anticancer drug for patients with locally advanced rectal 
cancer in both neo and adjuvant treatment setting [25]. Since 5-FU can act as a radio 
sensitizer at the cellular level, it has been extensively used concomitantly with radiation 
[26]. 
5-FU is a fluoropyrimidine antimetabolite most frequently administrated by continuous 
intravenous (Iv) infusion (225–300 mg/m2/day), or alternatively in its oral form – 
Capecitabine [13]. 
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 5-FU rapidly enters the cells where is converted into three active metabolites: 
fluorodeoxyuridine monophosphate (FdUMP), fluorodeoxyuridine triphosphate (FdUTP), 
and fluorouridine triphosphate (FUTP), which have different effects. FdUMP inhibits the 
action of thymidylate synthase (TS), FUTP disrupts RNA synthesis, and FdUTP is directly 
misincorporated into DNA (Figure 1.2) [27]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TS is a nucleotide synthetic enzyme, that catalyses the reductive methylation of 
deoxyuridine monophosphate (dUMP) to deoxythymidine monophosphate (dTMP) with 
the reduced folate 5,10-methylenetetrahydrofolate (CH2THF) as the methyl donor, 
creating the only de novo source of thymidine monophosphate (TMP), which is necessary 
Figure 1.2- Representative scheme of 5-Fluorouracil metabolism.  
5-FU is taken up into cells and converted into three main active metabolites: fluorodeoxyuridine 
triphosphate (FdUTP), fluorouridine triphosphate (FUTP) and fluorodeoxyuridine monophosphate 
(FdUMP). An alternative activation pathway involves the thymidine phosphorylase (TP) catalysed 
conversion of 5-FU to fluorodeoxyuridine (FUDR), which is then phosphorylated and converted into 
FdUMP. 5-FU can inhibit RNA synthesis in a pathway that involves its transformation into FdUTP, can 
cause DNA damage by directly misincorporation of FUTP and by FdUMP binding to the nucleotide-
binding site of thymidylate synthase (TS), inhibiting DNA synthesis. Dihydropyrimidine dehydrogenase 
(DPD)-mediated conversion of 5-FU to dihydrofluorouracil (DHFU) is the rate-limiting step of 5-FU 
catabolism in normal and tumor cells. Up to 80% of administered 5-FU is metabolized by DPD in the 
liver. Adapted from [3]. 
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Figure 1.3- Mechanism of thymidylate synthase (TS) inhibition by 5-Fluorouracil.  
Thymidylate synthase (TS) catalyses the conversion of deoxyuridine monophosphate (dUMP) to 
deoxythymidine monophosphate (dTMP) with 5,10-methylene tetrahydrofolate (CH2THF) as the 
methyl donor. In the presence of the 5-FU active metabolite FdUMP it binds to the nucleotide-binding 
site of TS and forms a stable ternary complex with TS and CH2THF, blocking access of dUMP and 
inhibiting dTMP synthesis. This results in deoxynucleotide (dNTP) disequilibrium and DNA damage. 
Adapted from [3]. 
for DNA replication and repair [28, 29]. Due to its crucial importance to DNA replication, 
TS is an important target for fluoropyrimidine drugs, such as 5-FU.  
TS contains a nucleotide-binding site and a binding site for CH2THF. The 5-FU metabolite 
FdUMP binds covalently to the active site of TS forming a stable ternary complex with the 
enzyme and with CH2THF, blocking the binding of the normal substrate dUMP thereby 
inhibiting dTMP synthesis. As a consequence, there is a depletion of dTMP which induces 
deoxynucleotides disequilibrium, restricting proper DNA replication and repair 
mechanisms, resulting in DNA damage and inducing cell-cycle arrest (Figure 1.3) [3, 30]. 
 
 
 
 
 
Other relevant enzymes involved in 5-FU metabolism are dihydropyrimidine 
dehydrogenase (DPD) and thymidine phosphorylase (TP) (Figure 1.2). DPD is the rate-
limiting enzyme in 5-FU catabolism which converts 5-FU to dihydrofluorouracil (DHFU). 
Over 80% of the administered 5-FU is normally catabolised primarily in the liver, where 
DPD is abundantly expressed [31]. TP function is related with an indirect metabolization 
pathway of 5-FU to FdUMP by 5-fluoro-2'-deoxyuridine (FUdR).  
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1.3.2 Chemo-resistance to 5-fluorouracil 
Poor response rates to CT are mainly due to the acquisition of resistance mechanisms. 
Chemo-resistance is believed to be the main cause of treatment failure in around 90% of 
patients with metastatic malignant diseases [32]. Therefore, it is important to 
characterize the biological factors that are involved in these mechanisms since they are 
directly correlated with treatment responses.  
Regarding 5-FU, the expression of TS influences its therapeutic efficacy. In gastric cancer 
and CRC, data showed that patients whose tumors did not respond to treatment had the 
mean TS protein level significantly higher (14.5 versus 1.36, p< 0.01) comparing with 
samples from patients with responsive disease. The same result was achieved concerning 
the expression levels of TS messenger RNA (mRNA) (0.17 versus 0.60 arbitrary units, p< 
0.01). Thus high expression and protein levels were correlated with lack of response to 5-
FU [33]. In accordance, other studies show that low tumoral TS expression improves the 
efficacy of 5-FU based therapies, since TS expression was significantly associated with OS 
(p= 0.002) [34, 35]. 
TS protein expression is regulated at the post-transcriptional level, by inhibition of a 
negative feedback mechanism in which ligand-free TS binds to its own mRNA inhibiting its 
own translation. When stably bound to FdUMP, TS can no longer bind to the mRNA, 
maintaining a constant level of free enzyme [27, 36]. This suggests that the amount of 
FdUMP and the acute increase in TS expression (that facilitates the recovery of the 
enzyme activity) in response to cytotoxic agents, may play a role in the development of an 
important resistance mechanism [33]. 
Also in CRC, low levels of DPD mRNA expression were found in all 5-FU responders 
compared with higher levels in the 5-FU non-responders. Furthermore, few studies also 
demonstrated that high levels of TP mRNA also correlates with resistance to 5-FU [37]. 
However, there is no correlation between TS, DPD, and TP expression values in CRC, 
indicating that they are independent predictive markers of 5-FU response [38]. 
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1.3.3 5-FluorouraciI pharmacokinetics  
Regarding 5-FU pharmacokinetics, parameters like steady-state concentrations (Cpss) and 
total body clearance have been studied in order to determine the benefits in terms of 
clinical response and toxicity obtained by prolonging the drug delivery period and/or 
increasing the blood concentration [39].  
Following a continuous drug infusion, the concentration of the drug in the plasma will 
increase until the rates of drug administration and drug elimination are equal. When the 
plasma concentration is constant Cpss is reached.  
Cpss of 5-FU in plasma, measured in patients after continuous 5-FU infusion of 200 
mg/m2/day ranged from 0,39 µM to 66,3 µM [40, 41]. This fact is extremely important, 
since it has been reported that standard CT regimens, are not only cytotoxic but also able 
to induce cellular senescence, a state of irreversible proliferative arrest [42, 43]. This 
means that at low levels CT drugs can have different effects on the tumor cells.  
1.4 Cellular senescence 
Senescence derives from the Latin word senescere that means ‘to grow old’. When 
applied to life sciences, senescence was first defined as a set of deteriorative processes 
resulting from biological aging, where an organism progressively accumulates changes in 
their molecular and cellular structure, consequently altering their metabolism and 
resulting in death [44, 45]. However, the biological concept of senescence has evolved 
substantially. 
In 1961 Hayflick and Moorhead [46] described for the first time that normal somatic cells 
have limited proliferation ability, and that cells that initially proliferate at  a normal rate 
gradually lose the ability to proliferate despite optimal culturing conditions. These results 
were later confirmed, leading to the hypothesis that cellular senescence is the cell 
mechanism responsible for the finite life time of human diploid cells [47]. 
The process observed by Hayflick is named replicative or cellular senescence, and occurs 
due to the progressive shortening of the telomeres in proliferating cells, leading to a 
proliferation limit. The first report suggesting that telomere shortening is the major 
mechanism responsible for replicative senescence came in early 1990s [48] and it is 
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currently the only known endogenous mechanism of senescence induction. The majority 
of normal cells, from all vertebrate species, undergo replicative senescence, although the 
number of cell divisions before senescence can be relatively variable [49]. 
Telomeres are regions of tandemly repeated hexanucleotide sequences (5'-TTAGGG-3' in 
vertebrates). Many cellular factors directly (e.g. TRF1/TRF2) and indirectly (e.g. shelterin-
complex, PinX, Apollo and tankyrase) interact with telomeres, influencing telomere 
structure and function [50]. Located at the ends of chromosomes, these regions prevent 
cells from recognizing chromosome ends as double strand breaks (DSBs), avoiding the 
fusion with other chromosomes ends by DNA-repair mechanisms [51]. Therefore, 
telomeres are essential to maintain the stability and integrity of  eukaryotic genomes 
[52]. During replication, DNA polymerase fails to completely replicate DNA ends, a 
process known as the “end-replication problem”, which contributes to telomere 
shortening. As a result, cells lose between 50 to 200 base pairs of telomeric DNA during 
each round of DNA replication [51]. When telomeres reach a critically short length, their 
protective function is disrupted, triggering a sustained DNA damage signal that will 
eventually cause the cell to stop dividing.  
Cancer and germline cells, unlike most somatic adult cells, express telomerase, a cellular 
reverse transcriptase whose function is to add telomeric DNA to the chromosome ends, 
elongating the telomeres and solving the problem of the “end-replication” [52]. 
Telomerase however, either endogenous or ectopically expressed (to immortalize primary 
cells in vitro), does not completely impair senescence since it can be induced by multiple 
extrinsic factors besides telomere erosion. This type of telomere-independent senescence 
has been termed stress-induced or premature senescence, as it is established prior to 
telomere shortening-induced senescence [53].  
Currently, the concept of cellular senescence is applied to any type of irreversible 
proliferation arrest. Multiple extrinsic factors such as DNA damaging agents (e.g. ionizing 
radiation and chemotherapy agents), oxidizing agents, and oncogene activation, have 
been found to trigger telomere-independent senescence [54-57]. Therefore, ‘replicative 
senescence’ refers to telomere-derived senescence and ‘stress-induced (or premature) 
senescence’ (SIS) refers to senescence induced by exogenous factors [2].  
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1.4.1 Signaling pathways mediating senescence 
Independently of the trigger factor, senescence state derives from DNA damage response 
(DDR) activated signalling cascade, due to the occurrence of single strand breaks (SSB) or 
double strand breaks (DSB). 
DDR is crucial to preserve and maintain genome integrity. Besides activation of DNA 
repair pathways, DDR can also induce the arrest of cell cycle progression by activating 
checkpoint proteins. This allows the cell time to repair the DNA damage, preventing the 
replication of damaged DNA.  
The DDR (Figure 1.4) pathway is activated by two major sensors of damage: the MRE11–
RAD50–NBS1 (MRN) complex, which detects DNA DSBs, and replication protein A (RPA) 
that, together with RAD9–RAD1–HUS1 (9-1-1) complex, which detects exposed regions of 
single-stranded DNA. These damage sensors recruit apical kinases according to the type 
of lesion. DSBs signal leads to the activation of ataxia-telangiectasia mutated (ATM), 
whereas single-stranded DNA regions engage ataxia telangiectasia and Rad3-related (ATR) 
[58]. The recruitment of ATM or ATR leads to phosphorylation of histone variant H2AX on 
Ser139 (known as γH2AX). In the case of DSBs, γH2AX is required to activate mediator of 
DNA damage checkpoint 1 (MDC1) and p53-binding protein 1 (53BP1) that amplify the 
DDR by recruiting additional ATM complexes in a positive feedback loop. In the case of 
single-stranded DNA damage, ATR kinase activity is enhanced by the 9-1-1 complex and 
by topoisomerase-II-binding protein 1 (TOPBP1). Breast cancer 1 (BRCA1) is then 
phosphorylated by ATM or ATR, and recruited to the sites of DNA damage [4, 59]. After 
amplification of the DDR signal, ATM and ATR activate by phosphorylation the checkpoint 
kinases 2 (CHK2) and CHK1, respectively. CHK2 and CHK1 will establish the 
communication between DDR-associated factors and the cell cycle machinery through 
phosphorylation and activation of downstream effectors such as p53 and the cell division 
cycle 25 (CDC25) phosphatases [4, 53]. The interaction between the ATM and ATR 
signalling pathways is complex. The ATR-Chk1 pathway can be activated in response to 
DSBs when single stranded DNA is generated on broken DNA ends. On the other hand, 
single-strand nicks can result in DSBs when, during replication of damaged DNA, they are 
encountered by leading-strand DNA polymerases. Therefore these pathways are 
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Figure 1.4- The DNA damage response.  
Double-strand breaks are recognized by the MRE11–RAD50–NBS1 (MRN) complex and lead to the 
activation of ataxia–telangiectasia mutated (ATM) and subsequent amplification of the response 
through the recruitment of other DNA damage response proteins. Activated ATM phosphorylates (P) 
checkpoint kinases2 (CHK2), which in turn phosphorylates p53 and other substrates. Other forms of 
DNA damage lead to the generation of single-stranded regions that are detected by replication protein 
A (RPA) and RAD9–RAD1–HUS1 (9-1-1) complex. This attracts the ataxia–telangiectasia and Rad3-related 
(ATR) which phosphorylates and is phosphorylated by 9-1-1 complex. ATR activates downstream 
substrates including checkpoint kinases1 (CHK1). In addition, ATM and ATR phosphorylate the histone 
variant H2AX on Ser139 (γH2AX). DDR signal amplification is undertaken by damage checkpoint 1 
(MDC1), p53-binding protein 1 (53BP1), 9–1–1 complex and topoisomerase-II-binding protein 1 
(TOPBP1). Adapted from [4]. 
frequently activated simultaneously in cells exposed to genotoxic stresses, including 
ionizing radiation and chemotherapy agents [60]. 
 
 
 
 
 
 
 
Ultimately, when the injury is extremely severe, the DDR may prone cells  to apoptosis, a 
program of cell death that is used to eliminate damaged cells in a controlled manner that 
minimizes damage and disruption of the neighbour cells [61]. Also, the DDR-initiated 
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proliferation arrest can be either temporary, allowing cells to repair DNA damage and to 
resume their cycle, or persistent (cellular senescence), caused by the accumulation of 
unrepaired DNA lesions that fuel a sustained DDR signalling. It is still unclear what tips the 
balance towards the pathways that lead to either apoptosis or senescence, but important 
determinants may include cell type and the intensity, duration and nature of the damage 
[45, 59].  
1.4.1.1 p53 and pRb, two master regulators of senescence 
Tumor suppressor genes encode for proteins that impair cell neoplastic transformation. 
These proteins provide a defence mechanism against oncogenic mutations and induced 
DNA damage, preventing transformation by forcing cells into apoptosis or cell cycle 
arrest. Full blown tumor onset depends on the inactivation or deletion of these genes 
[62].  
Consistent with their roles in preventing the proliferation of genetically modified cells, 
two different tumor suppressor proteins, p53 and retinoblastoma protein (pRb), have 
been shown to be deeply involved in the onset and maintenance of senescence [2]. Back 
in 1991 it was shown for the first time that p53 and pRb are two major regulators of 
senescence, since suppression of both proteins leads to an inhibition of cell cycle arrest 
allowing cells to bypass senescence [63]. Since then, the role of p53 and pRb in the 
activation of downstream molecular networks in mouse and human has been subject of 
extensive research [2]. 
Experiments with senescent mouse embryonic fibroblasts (MEFs) showed that 
suppression of p53 is sufficient to escape senescence [64]. On the other hand, although 
inactivation of pRb alone did not affect senescence, simultaneously with the inactivation 
of the pRb family proteins p107 and p130 it impaired the cells’ capability to perceive the 
senescence-inducing signal, strongly increasing their proliferation rate [65]. Moreover, 
acute loss of pRb in senescent cells lead to a reversion of the senescence phenotype [66]. 
Globally, these results indicate that p53 and pRb are not only necessary for the onset of 
senescence but are also needed to maintain it. In addition, these evidences suggest a 
linear model of pathway activation, in which stress-induced p53 activation leads to pRb 
downstream activation [2].  
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However, experiments in human fibroblasts suggest that either a linear or parallel 
activation process can occur [67-69].It is currently accepted that the activation of each 
tumor suppressor protein can be related to different stimuli and be cell type and species 
specific [45]. Therefore, pathways downstream of p53 and pRb can be activated 
independently or simultaneously, cross-regulating each other and mediating senescence 
onset and maintenance [70, 71].  
Different DDR inducers can lead to senescence mainly through the activation of the p53 
pathway [72], with the first evidence being dated back to 1984 where ultraviolet (uv) 
irradiation caused severe genomic stress and increased p53 levels in non-transformed 
mouse cells [73].   
The p53 pathway is regulated at several levels by different proteins, but the most 
important p53 regulator is the E3 ubiquitin-protein ligase MDM2 (in humans is frequently 
called HDM2) [74]. MDM2 forms a complex with p53 and inhibits its activity in different 
ways. MDM2 can bind the transcriptional activation domain of p53 and block its ability to 
regulate target genes [75, 76], and can also promote the ubiquitylation and subsequent 
proteosome-mediated degradation of p53, either way inhibiting p53-dependent 
senescence [77, 78]. Moreover, the MDM2 gene has a p53 DNA-binding site, making it a 
direct transcriptional target of p53. Therefore, there is an auto-regulatory negative-
feedback loop that regulates the expression of MDM2 and the activity of p53 [79, 80].  
In proliferating cells p53 is kept at basal levels that rapidly increase upon genomic stress. 
This regulatory mechanism is mainly controlled via the constant action of the MDM2–p53 
loop in which excessive p53 activity triggers the production of MDM2 that in turn will 
promote p53 degradation and extinguish p53 cellular activity [81]. This switch in p53 
levels and activity upon stress makes p53 into one of the most important genomic 
guardians and protectors against cancer progression. 
The Rb protein family is composed of pRb, p107 and p130, and is involved in the control 
of G1-S transition. pRb negatively regulates E2F transcription factors, preventing the 
activation of genes necessary for G1-S transition and cell cycle progression [82]. Cells 
lacking pRb show aberrant proliferation and increased genomic instability [83]. It was 
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Figure 1.5- Structure of the INK4a/ARF and INK4b loci.  
The INK4b/Arf/INK4a locus includes two different genes. The splicing patterns and encoded proteins 
are represented. Two distinct promoters transcribes for exons 1α (INK4a) and 1β (Arf) and result in 
alternatively spliced transcripts that share exons 2 and 3. Although shared, different open reading 
frames within exon 2 give rise to two distinct protein products. Adapted from [1]. 
recently demonstrated that pRb has a unique and non-redundant function in senescence 
by regulating a particular subset of E2F targets and preventing DNA replication [83]. pRb 
specifically represses transcripts associated with replication, while p107 and p130 repress 
the transcription of DNA replication factors associated with quiescence but not with 
senescence.  
1.4.1.2 The Arf-p53- p21WAF1 pathway. 
Upstream control of p53 can be mediated by the DDR, via ATM/ATR and CHK2/CHK1 
proteins, or by alternative reading frame (Arf) protein [84]. Arf is encoded by the 
INK4a/Arf locus (Figure 1.5). Formally designated CDKN2A and CDKN2B, the locus 
includes three closely linked tumor suppressor genes (INK4a, INK4b, and ARF) that trigger 
the anti-proliferative activities of both pRb and p53 [85]. INK4a and INK4b encode for 
p16INK4a and p15INK4b, respectively, and Arf encodes for p14Arf (p19Arf in mouse). While 
p16INK4A is encoded by the α transcript containing exon 1α, exon 2 and exon 3, p14Arf is 
encoded by the β transcript comprised by exon 1β and exon 2 and 3. These two exons are 
common to p16INK4A under a different promoter and translated in an alternative reading 
frame [86]. 
 
 
 
 
Mice lacking only the 1β exon, expressing only p16INK4a, showed high tumor susceptibility, 
and their phenotype was similar to that of p53 null mice, demonstrating ARF’s tumor 
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suppressor functions [87]. Since p53-deficient cells are resistant to ARF- induced arrest, 
ARF is considered a positive upstream regulator of p53 [87]. In fact, ARF interferes directly 
with MDM2 function in the nucleolus, inhibiting the E3 ubiquitin-protein ligase activity of 
MDM2 and therefore increasing p53 stability and activating the p53-mediated 
transcriptional program [88, 89]. 
Despite the fact that several stress signals that can activate the p53 pathway have been 
identified, those requiring Arf still need to be clarified. It was previously demonstrated 
that p19Arf knockout (KO) MEFs have impaired DNA damage and microtubule disruption 
[90]. It was also shown that in normal human fibroblasts Arf expression is induced in 
response to ionizing radiation, and that endogenous p14Arf can bind directly to p53 
independently of HDM2 as an immediate response to DNA damage, suggesting that Arf 
can also function as a cofactor for p53 transactivation. [91]. In addition, high expression 
of Arf was also observed in Ras-induced senescent MEFs, and is considered necessary for 
telomeric and non-telomeric-derived senescence [87, 89]. Although Arf activation seems 
to be stress dependent, little is known about  its physiologic context [2].  
In mouse models, Arf inactivation is comparable to p53 inactivation, preventing 
senescence and reinforcing its role as tumor suppressor [87]. The same is not applied to 
human cells, where the role of Arf is not so clear [2].  
Given the role of INK4a/ARF in modulating activities of pRb and p53, it is not surprising 
that deletion of the locus is frequently detected in many distinct tumor types [92].  
Most genes that are downstream targets of p53 encode for proteins that regulate cell 
cycle checkpoints, apoptosis and senescence. CDKN1, that encodes for cyclin dependent 
kinases (Cdk) inhibitor protein p21WAF1, is directly transactivated by p53 [93]. The p21WAF1 
protein is a member of the CIP/KIP family of Cdk inhibitors and in the context of 
senescence, either replicative or stress-induced, is considered one of the most important 
downstream targets of p53 [94]. All p21WAF1’s functions are related to cell cycle inhibition. 
It not only inhibits cyclin/Cdk complexes, but also blocks proliferating cell nuclear antigen 
(PCNA), inactivates pRb through proteosome-mediated degradation and inhibits cyclin B1 
[95, 96]. Binding of the N-terminal region of p21WAF1 to Cdk2 inhibits the formation of the 
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Figure 1.6- Signal transduction pathways mediating senescence.  
Sequential activation of the Arf-p53-p21
WAF1
 and p16
INK4a
-pRb signaling cascades. Increased 
transcriptional activity of p53 is achieved by phosphorylation (P), performed by the ATM/ATR and 
CHK2/CHK1 proteins, or by the p14
Arf
 product of the INK4a/Arf locus, which sequesters E3 ubiquitin-
protein ligase HDM2. By its turn HDM2 regulates p53 activity by a negative feedback loop mechanism. 
Senescence is triggered by retinoblastoma (pRb) hypophosphorylation and consequent silencing of E2f 
target genes. pRb is activated either by p21
WAF1
, or by the p16
INK4a
 product trough inhibition of the cyclin 
E/Cyclin dependent kinase 2 (CycE/Cdk2) and cyclin D/Cyclin dependent kinase 4/6 (CycD/Cdk4/6) 
complexes, respectively. Adapted from [2]. 
cyclin E/Cdk2 complexes, thereby impairing pRb phosphorylation. The accumulation of 
unphosphorylated pRb prevents the release of E2F transcription factors from pRb/E2F 
complexes, blocking cells in G1 (Figure 1.6) [97]. Primarily, p21WAF1 activates cell cycle 
checkpoints in G1 and in G1/S [94]. However, in response to DNA damage, p21WAF1 
activates the G2/M checkpoint by degradation of cyclin B1, inducing a G2 cell cycle arrest 
[98].  
Nevertheless, senescence is not impaired in MEFs carrying a null mutation in p21WAF1, 
suggesting a non-essential role for p21WAF1 or the existence of other mechanisms that 
compensate for its loss of function [99].  
 
 
 
 
 
1.4.1.3 The p16INK4a-pRb pathway 
p16INK4a, also encoded by the INK4a/ARF locus, is a Cdk inhibitor that forms a complex 
with Cdk4/6, inhibiting the interaction with cyclin D through a conformational alteration. 
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Abrogation of the activation of Cdk4/6 maintains pRb in the hypophosphorylated active 
form (Figure 1.6) [100].  
The p16INK4a promoter is not normally expressed in differentiated tissues. However, it can 
be induced by stress conditions and was found to be highly expressed in senescent cells 
[101]. p16INK4a overexpression was first described during replicative senescence [102] and 
later in response to oncogenic Ras activation [57].  
Stimuli that trigger a DDR can also activate the p16INK4a-pRb pathway, as a secondary 
response after activation of the p53 pathway [103]. As previously mentioned, the 
signalling pathway engaged at the onset of senescence can be different according to the 
stress signal (specific combination and severity), cell type and species. If, on one hand, 
telomere disruption activates the p53 pathway, on the other hand, other senescence-
inducing stimuli, like oncogenic Ras, may act primarily through the p16INK4a-pRb pathway 
[67, 104].  
p16INK4a KO mice are more prone to develop a variety of spontaneous long latent tumors 
[105]. In humans, introduction of activated Ha-ras into p16INK4a inactivated primary 
fibroblasts can induce neoplastic transformation [104]. All the evidences point to p16INK4a 
as a key player in tumor suppression and a mediator of the senescence process.  
1.4.2 Senescence-associated heterochromatic foci 
Senescent cells suffer a nuclear rearrangement correlated with critical gene expression 
alterations that will epitomize activation of senescence regulators and silencing of 
proliferation-associated genes.  
As described before, pRb is a crucial effector of senescence and a key component in the 
irreversibility of the cell cycle arrest. The role of p16INK4a-pRb pathway in senescence also 
involves chromatin remodelling and formation of heterochromatin regions, known as 
senescence-associated heterochromatic foci (SAHF). At these regions heterochromatin is 
condensed, modified and transcriptionally silent. SAHF formation appears to be 
dependent on the integrity of the p16INK4a-pRb pathway, in which hypophosphorylated 
active pRb silences E2F target genes [106]. 
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Initially, histone chaperones like histone repressor A (HIRA) and heterochromatin protein 
1-γ (HP1γ) are recruited to specific subnuclear organelles, the acute promyelocytic 
leukaemia (PML) nuclear bodies. After HIRA’s translocation into PML bodies, chromatin 
condensation occurs, trimethylation of lysine 9 in histone 3 (H3K9me3) accumulates, and 
HP1 and histone H2A variant (a family of three related proteins, macroH2A1.1, 1.2 and 2) 
are recruited to SAHF [107, 108].  
Proliferation-promoting genes, such as E2F target genes (e.g. cyclin A), are silenced by 
incorporation into the SAHF, contributing to the irreversibility of the proliferative arrest 
that characterizes senescence [106]. Senescent cells are, therefore, unable to re-enter the 
cell cycle, even in a pro-mitogenic environment. These features distinguish senescence 
from quiescence, a non-proliferative but reversible state [106].  
Although senescence can be a stress-response mechanism to prevent proliferation, some 
senescent cells also become resistant to certain apoptotic signals. For example, senescent 
human fibroblasts do not undergo ceramide-induced apoptosis, and also become 
resistant to programmed cell death caused by growth factor deprivation and oxidative 
stress [109, 110]. In contrast, Fas death receptor activation is able to induce apoptosis in 
these cells [111]. Nevertheless, the molecular pathways involved in resistance to 
apoptosis are still poorly understood. Alterations in gene expression may contribute to 
inhibit, promote or establish apoptosis [112]. Furthermore, evidences show that p53 
might preferentially transactivate genes that arrest proliferation, rather than those that 
trigger apoptosis in senescent fibroblasts [113].  
 
1.4.3 Senescence-associated secretory phenotype  
Senescent cells remain metabolically active, acquiring a designated senescence-
associated secretory phenotype (SASP), with a characteristic senescence-associated 
secretome (SAS) composed by several pro-inflammatory cytokines, chemokines, growth 
factors, and proteases [114].  
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Persistent DNA damage seems to be required for induction of SASP. In fact, ectopic 
overexpression of p21 or p16INK4a triggers senescence without SASP, while DNA damage, 
dysfunctional telomeres, epigenomic disruption, mitogenic signals, oxidative stress, and 
other senescence-DNA damage inducing stimuli induce a SASP [115, 116].  
Moreover, SASP can be different according to the inducing stimulus. Genetic alterations 
like loss of p53, or activation of Ras, that induces senescence by indirect DNA damage due 
to hipper-replication [117], lead to an accelerated acquisition of a more prominent SASP 
[118].  
The first evidences of alterations in the cell secretome due to senescence were reported 
in 1991 where microarray analysis revealed a strong inflammatory secretome of 
fibroblasts undergoing replicative senescence [119].  
Currently it is well established that normal and epithelial tumor cells have a SAS after 
genotoxic-induced senescence [118, 120]. In addition, it was demonstrated in vivo that 
DNA-damaging chemotherapy-induced senescent human prostate cancer cells have a SAS 
[118]. 
Using antibody-array technology, a large-scale characterization of SAS from normal 
fibroblasts, normal epithelial cells, and epithelial tumor cells after genotoxic stress, 
showed that SAS molecules can be divided into three major categories: soluble signaling 
factors (interleukins, chemokines, and growth factors), secreted proteases, and secreted 
insoluble proteins/extracellular matrix (ECM) components [114, 118]. Overall, these 
factors can induce mechanisms capable of altering cell fate of neighboring cells and 
modify the tissue microenvironment. Despite of a substantial overlap in the SAS 
composition among different cells and tissues, like interleukin (IL)-8, the SAS and its 
effects seem to be cell and tissue-type specific [114].  
The SAS has powerful paracrine effects inducing a variety of cellular responses. With 
several cytokines and chemokines in SAS, it can contribute to modulate immune 
responses, targeting the senescent cells for elimination by the immune system, attracting 
and activating natural killer cells, macrophages and T cells. In addition to an eventual 
clearance of senescent cells, local immune reactions seem to be stimulated by the SAS, in 
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order to eliminate oncogene-expressing cells [121, 122]. Recent evidences suggest that 
SAS molecules can also establish a communication with the surrounding cells in injured 
tissues promoting the regeneration and/or repair of the tissue lesion. In fact, in two 
different mouse models of acute liver injury and skin wounding, it was shown that the 
presence of senescent cells within the damaged tissue was correlated with limited 
development of fibrosis during tissue repair, contributing to an optimal tissue repair [123, 
124]. 
There are also evidences that suggest an autocrine effect of SAS. In the case of Ras or 
BRAF-induced senescence in human diploid fibroblasts, the pro-inflammatory cytokines 
IL-6 and IL-8, and insulin-like growth factor-binding protein 7 (IGFBP7) strengthen the 
proliferation arrest. In fact, IL-6 is required for both induction and maintenance of 
oncogene-induced senescence and IGFBP7 has a central role in BRAF-mediated 
senescence [125, 126].  
In contrast to the above described beneficial effects of SAS, several findings suggest that 
also some detrimental effects can occur. The proliferative rate, migration and invasion of 
premalignant and malignant cells are enhanced when co-cultivated with senescent 
fibroblasts or incubated with their conditioned medium [127].  
In breast cancer, senescent human fibroblasts can stimulate the proliferation of 
premalignant and malignant mammary cells in vitro, and the formation of tumors in mice 
[128, 129]. Stromal cells exposed to low-doses of ionizing radiation have been shown to 
contribute to breast carcinogenesis by disturbing the mammary microenvironment and 
inducing inappropriate epithelial cell growth in the mammary gland. Part of these 
alterations may be related to the secretion of multiple matrix metalloproteinases (MMPs) 
that completely disrupted the mammary ductal morphogenesis as demonstrated in a 
three-dimensional co-culture system [130]. Moreover, high levels of IL-6 and IL-8 as well 
as hepatocyte growth factor (HGF), urokinase-plasminogen activator receptor (uPAR) – a 
serine protease and regulator of the plasminogen activation pathway- and MMPs, 
secreted by senescent fibroblasts are apparently responsible for enhancing the 
invasiveness potential of a panel of breast cancer cell lines conferring metastatic 
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properties on epithelial cells, typical of the epithelial-mesenchymal transition (EMT) [118, 
129]. 
Human prostate stromal cells that undergo senescence secrete a subset of paracrine 
factors capable of favoring epithelial cells to hyper-proliferate in vitro. In fact, fibroblast 
growth factor 7 (FGF7), HGF, and amphiregulin (AREG) were elevated in the extracellular 
environment of the senescent prostate fibroblasts and apparently related with the 
growth-promoting effects [131]. 
SASP components can also stimulate pro-angiogenic events. Using a xenograft mouse 
model of breast cancer cells, it was shown that blood vessel density was significantly 
higher when tumors developed in a senescent microenvironment, and that endothelial 
cells were more invasive when incubated with conditioned medium from senescent 
fibroblasts [132].  
The complexity of studding the effects of SAS is reflected in the multiple functions of the 
same SAS component. Whereas IL-6 is required, through an autocrine way, to oncogene-
induced senescence, the same senescent cells produce IL-6 that will act as a pro-
mitogenic factor through a paracrine fashion [125]. 
In melanoma, senescent cells secrete several chemokines that may contribute to the 
emergence of cancer stem cells and therefore contribute to drug resistance, and tumor 
spreading, as previously reported [133].  
Globally, senescence acts as tumor suppressor mechanism, via an irreversible cell cycle 
arrest. Some SAS factors contribute to the onset of senescence and to stimulate the 
immune system in a cell non-autonomous way. On the other hand, a senescent 
microenvironment creates cancer permissive conditions and stimulates cancer cell 
aggressiveness. In particular, the SAS paracrine effects can induce proliferation and 
invasion of pre and neoplastic cells, promoting cancer progression. Therefore, according 
to the physiological context, a senescent cell can be beneficial or detrimental to the 
neighboring cells. The specific tissue, genetic profile at the time of senescence, and age-
related pathologies, like chronic inflammation, are all factors that contribute to this dual 
role of senescence and may be important key players to clarify this complex paradox. The 
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challenge is to understand the benefits of senescence in a specific context and to 
suppress its negative effects.  
1.4.4 Markers of cellular senescence 
The identification of the cellular state of senescence relies in different markers that can 
be used in cultured cells and/or in tissues.  
Senescent cultured cells exhibit distinct morphological alterations, such as enlarged and 
flattened cell shape, with an increase in cytoplasmatic granularity and a prominent 
nucleus - hallmarks of the senescent phenotype (Figure 1.7). 
 
 
 
 
 
Figure 1.7- Representative images of senescent cells with distinct morphological features in vitro. 
HCT 116 colon cancer cells become senescent after exposure to 5 µM of 5-FU for seven days. Senescent 
cells exhibit a characteristic morphology, with enlarged and flattened cell shape and increased granularity. 
Black arrows indicate the blue cytoplasmatic staining that results from degradation of a chromogenic 
substrate, 5-bromo-4-chloro-3-indolyl β-d-galactopyranoside (X-Gal) by senescence-associated β -
galactosidase at pH 6.0. This enzymatic-based detection method is the most widely accepted biomarker of 
senescence.  
 
However, with some exceptions as reported for large cell change of hepatocytes, the 
architectural aspects of cohesive tissue organization lead to lack distinctive morphological 
features of senescent cells present in tissues [53, 134, 135].  
The most extensively used biomarker of senescence is the cytochemical detection of β-
galactosidase activity at pH 6.0, termed senescence-associated β- galactosidase (SA-β-gal) 
[136]. The increased activity of this enzyme observed in senescent cells reflects protein 
overexpression and accumulation at the lysosomas [137]. SA-β-gal is able to cleave the 
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chromogenic substrate X-Gal (5-bromo-4-chloro-3-indolyl β-d-galactopyranoside), leading 
to the precipitation of an insoluble blue dye visible under a bright field microscope (see 
Figure 1.7) [136]. Activity of SA-β-gal above a threshold level turns it detectable at 
suboptimal pH 6.0 (pH 4.0 is the optimal), contributing for the specificity of this marker. 
The increase in SA-β-Gal activity is specific of senescent cells, either triggered by telomere 
erosion, DNA damage agents, oncogenic signals, or overexpression of tumor suppressors 
such p16INK4a and ARF [135]. Since it is not observed in pre-senescent or quiescent cells, 
detection of SA-β-gal activity is considered a reliable marker for detection of senescent 
cells. [54, 138-141]. 
Nevertheless, detection of increased activity of SA-β-gal has been also reported in 
cultured cells under stress conditions, such as serum withdrawal, cell contact inhibition or 
high confluence, therefore senescent-independent [142]. Moreover, this biomarker 
cannot be applied to formalin-fixed paraffin-embedded (FFPE) tissues.  
Expression of proteins encoded at the CDKN2A locus has proved to be a useful marker of 
senescence in tissues. Increased expression of p16INK4a and Arf has been reported in 
murine tissues with oncogene-induced senescence, as well as in human malignant tissues 
[138, 143]. Consistently with the use of Cdk inhibitors to detect senescence, over-
expression of p21WAF1 was used in human non-alcohol-related fatty liver disease with 
positive results [144].  
γH2AX expression has also been used as a marker of cellular senescence [145]. However, 
since activated DDR can also induce DNA repair or apoptosis, γH2AX by itself can lead to 
false positive identification of senescent cells. Proteins associated with SAHF, such as 
HP1γ and macroH2A histone, have been also used to localize oncogene-induced 
senescent cells [138, 146].  
Up-regulated genes in oncogene-induced senescence, like basic helix–loop–helix 
transcription factor (DEC1) and decoy receptor 2 (DCR2), were also candidate markers of 
cellular senescence [138]. DEC1 and DCR2 are increased in premalignant neoplastic 
lesions of the skin, lung and pancreas, and highly correlated with the presence of SA-β-gal 
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activity and SAHF. However, an overexpression of these proteins is not observed in 
malignant tumors.  
Another candidate was lamin B1 [147]. Lamin B1 is decreased in different types of 
senescent cells, but not in quiescent and proliferating cells, independently of the trigger 
and signaling pathway involved in senescent onset. 
Recently, it was reported that Sudan-Black-B specific stain for lipofuscin can be used as an 
alternative or complementary method to SA-β-gal activity, in the identification of 
senescent cells, and suitable for FFPE tissues [148]. Lipofuscin is an autofluorescent 
lysosomal pigment that is associated with certain processes of ageing and which 
accumulates during senescence [149].  
However, both of these markers are less widely used, partly due to the lack of validated 
and reproductive protocols especially concerning FFPE samples, requiring further 
confirmation about the effective identification of senescent cells in an extensive range of 
samples.  
It is clearly evident that until now there is no universal marker of cellular senescence 
despite all efforts and intensive research over the years. When combined, several 
markers can be used to identify senescent cells in culture and in tissues. However, there is 
a lack for specificity, especially for tissues. The use of multiple senescence markers, 
combined with proliferation indicators like Ki-67 or the incorporation of 5-
bromodeoxyuridine (BrdU), which allows the identification of senescent areas with lower 
levels of proliferation, is still considered to be the best strategy to identify senescent cells 
[135]. This approach will reinforce an unambiguous detection of a senescent cell.  
1.4.5 Significance of cellular senescence in cancer  
Oncogenesis and cancer progression comprises several steps, the “hallmarks of cancer” 
[150]. Genomic instability, oncogenes activation and loss of tumor suppressors are all 
related events that eventually lead to a scenario of uncontrolled proliferative signaling, 
apoptosis resistance and replicative immortality. In addition, tumor microenvironment, 
where a niche of tumor-associated cells will stimulate angiogenesis and create permissive 
conditions for invasion and dissemination of malignant cells and the ability of tumor cells 
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to evade the host’s immune response, are also important factors leading to full 
malignancy. 
Since cellular senescence induces a state of irreversible cell cycle arrest, it is considered a 
tumor suppressor mechanism [151]. Evidences that senescence induction can suppress 
tumorigenesis have been reported in animal models and human cancers.  
In mouse mammary epithelial cells genetically manipulated for induction of premature 
senescence, it was observed suppression in the development of breast cancer, in young 
female mice exposed to the mouse mammary tumor virus [152]. In a mouse model of 
lung cancer, a conditional mutation in oncogenic Ras induced the development of 
multiple pre-neoplastic lung adenomas and adenocarcinomas. Senescent cells were 
observed in adenomas but not in adenocarcinomas [138]. Similar results were observed 
in animal models of pancreatic cancer and skin papillomas, suggesting that oncogene-
induced senescence may help to restrict tumor progression by arresting incipient tumors 
at a premalignant stage [138].  
It was also reported that pre-malignant human nevi and colon adenomas had senescent 
cells, which were substantially less present in malignant melanomas and colon 
adenocarcinomas [141, 153]. 
It is still not entirely clear how pre-malignant lesions progress to full malignancy. One 
hypothesis is that only a fraction of a heterogeneous population of cells is able to 
propagate successfully while many undergo apoptosis or senescence [138]. These cells do 
not fully attenuate the oncogenic signals and are at the origin of the malignant tumors. In 
the end it will be the balance between proliferative non-senescent and growth arrested 
cells that will determine the growth rate and tumor formation. Other possibility may 
imply that cells acquire specific mutations in tumor suppressor genes or suffer epigenetic 
changes that will enable cells to overcome the proliferative barrier imposed by cellular 
senescence and progress [154].  
Accordingly, it would be expected that neoplastic transformation is related to senescence 
program inhibition/overcome, nevertheless, it is now broadly described that tumor cells 
can be induced to undergo senescence upon DNA-damaging stimuli [155].  
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Furthermore, there are evidences that cellular senescence may even contribute to 
treatment outcome [54, 156]. However, its effects in the clinical outcome of cancer 
patients remain controversial due to contradictory results. Data from a mouse model of 
doxorubicin-treated mammary tumors showed that tumor cells induced by doxorubicin to 
undergo senescence were apoptosis-resistant and exhibit autocrine/paracrine activity 
likely contributing to cancer relapse [157]. Moreover, senescent cells were also detected 
after neoadjuvant CT in patients with malignant pleural mesothelioma or non-small cell 
lung carcinoma, and correlated with low OS and shorter PFS (p= 0.0098 and p= 0.022, 
respectively) in the first case, and with a decrease in OS (p= 0.04) in the second [158, 
159]. In contrast, CRC patients with senescent cells detected before treatment showed an 
increased susceptibility to TIS and better chemotherapy response [160]. Elucidation of the 
specific implications of senescence in the clinical outcome of cancer patients would 
definitely contribute to treatments improvement and to decrease the side effects of 
cancer therapy. 
Cancer incidence, like several other diseases, increases in with advanced age and the 
reasons are complex and depending on several factors, including accumulation of 
mutations in tumor suppressive and tumor promoting pathways and failure of the 
immune surveillance [116]. 
Cellular senescence is extensively reported as a common process that links ageing and 
cancer. Senescent cells are relatively rare in young organisms, but their number increase 
with age. Inducing factors like replicative exhaustion (telomere shortening), DNA damage 
(from endogenous and exogenous sources), loss of heterochromatin and inappropriate 
activation of mitogenic pathways, are more frequent with age [161]. The senescence 
accumulation is also related with clearance by the immune system. Either because 
elimination is incomplete (therefore senescent cells gradually accumulate) or because 
aged individuals generate senescent cells faster than their immune system can handle, 
senescence has been deeply implicated in ageing [162].  
Giving some examples, SA-β-gal positive cells were shown to increase with age in certain 
human tissues including skin, liver, adipose tissue, skeletal muscle and eye [136, 143, 
163].  
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Senescence comes with age. However, the inverse is also a reality. As expected, the 
chronic presence of cells that secrete several proteins with potent biological effects 
significantly alter the tissue structure and the local microenvironment not only 
contributing to the ageing process but also promoting age-related pathologies.  
By depleting the stem and progenitor cells from tissues, cellular senescence compromises 
tissue regeneration and repair and without the normal tissue turnover, organs start to be 
functionally compromised [164].  
Moreover, SAS factors severally affect vital processes like cell growth and migration as 
well as tissue architecture by inducing blood vessel formation and differentiation [129]. In 
addition, potent inflammatory cytokines are SAS components which may be linked to 
systemic increase of chronic inflammatory reactions known to enhance with age. Chronic 
inflammation is a hallmark of ageing that initiates or promotes most of the major age-
related diseases. 
Nevertheless, clear evidences that senescent cells lead to ageing remains circumstantial 
and we must take in consideration that organisms with germline deficiencies in p53, and 
consequently with cells that fail to undergo senescence, do not live longer, instead they 
die prematurely of cancer [165]. If on one hand, the beneficial effects on tumor 
suppression show promissing unexplored therapeutic targests, on the otherside, the 
detrimental effects of tissue degeneration must also be take in consideration [166]. 
Overall, and through SAS, cancer and other age-related pathologies can be promoted by 
the same mechanism. Attempting to explain how does senescence participates in three 
apparently opposing processes like tumor suppression, tumor promotion and ageing, 
several authors support the hypothesis that cellular senescence is an example of the 
evolutionary theory of antagonistic pleiotropy.  
Antagonistic pleiotropy has been used to explain how genetic features can have both 
beneficial and deleterious effects for species. This theory states that some genes, selected 
to maintain the health and fitness of young organisms, can have deleterious effects in 
aged organisms [44]. 
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Thus, DNA damage, telomere erosion or errors in proliferation pathways may cause 
senescent cells to accumulate, but their influence may become significant and deleterious 
only later in life when they reach sufficient numbers. The senescence response may have 
evolved to prevent cancer in most of the life span. However, in organisms that survive 
longer, the detrimental effects of senescent cells may become apparent [161].  
Moreover, mutations accumulate with age. With ageing, there is an increasing probability 
that senescent cells may occur nearby cells with oncogenic mutations. And despite 
protecting from cancer in young adults, favorable conditions can be created in order to 
senescent cells promote the growth and neoplastic progression of the mutant cells [167].  
Globally, senescence may benefit benefits organisms early in life by preventing cancer 
while their accumulation may be detrimental later in life stimulating ageing and age-
related diseases like cancer.  
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1.5 Aim of the thesis 
In rectal cancer patients, locoregional relapse and distant metastasis are major events 
leading to death. Tumor resistance to CRT, which is closely related to tumor relapse and 
metastatic dissemination, must be elucidated. Tumor cells and tumor-associated host 
cells, like fibroblasts, may became senescent in response to CT and acquire a SAS that can 
have deleterious effects on the tissue microenvironment, most likely contributing to 
tumor invasion and metastasis. We hypothesize that senescent tumor cells can also be 
deleterious by affecting neighbor tumor cells through a SAS-mediated paracrine 
mechanism. Following neoadjuvant CT, cell senescence may become an inducer of 
cancer relapse.  
For those reasons it is important to elucidate if tumor senescent cells also affect the 
neighbor cells fate and tumor progression. Understanding these effects will expand the 
possibilities for cancer therapy and modulation of therapeutic strategies. 
Therefore, the main goals of this thesis were: 
1. To study the effect of CT-induced senescent tumor cells SAS over non-senescent 
cancer cells, and its spatial range in the rectal cancer tissue microenvironment. 
2. To assess if therapy-induced cellular senescence correlates with rectal cancer 
relapse. 
a) To optimize and validate a biomarker for the detection of senescent cells in 
formalin-fixed paraffin-embedded (FFPE) tissues. 
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2.1 Abstract 
DNA damaging agents and ionizing radiation used in the therapy of human cancers may 
induce senescence of cancer cells. Senescent cells exhibit a secretory phenotype that can 
affect cancer cell behavior and, eventually, clinical prognosis. 
Here, we show that cultured colon cancer cells induced into senescence by exposure to 5-
fluorouracil exhibit a senescence-associated secretome capable of paracrine induction of 
epithelial-to-mesenchymal transition (EMT) in colon and rectal cancer cell lines, of 
increased cell invasion in vitro, and of increased chemosensitivity to 5-fluorouracil. 
Importantly, using laser-assisted microdissection we found that in rectal cancer samples 
from patients treated with neoadjuvant chemo-radiotherapy tumor cell niches enriched 
for senescent cells bookmark regions of increased expression of EMT-related genes (Slug, 
Snail, vimentin) when compared to nearby senescent-null control regions. Together, these 
data highlight the complex interplay between therapy-induced cancer cell senescence 
and two parameters with distinct prognostic value, namely increased chemosensitivity 
and EMT. 
Significance 
We provide first-hand, strongly suggestive evidence that senescent cancer cells emerging 
in the context of neoadjuvant chemoradiotherapy for rectal cancer influence the tumor 
microenvironment by promoting EMT via short range interactions. 
We propose that a combined assessment of senescence and EMT may become a useful 
prognostic tool after chemoradiotherapy for rectal cancer. 
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2.2 Introduction  
Distant relapse affects about 15 to 20% of patients diagnosed with locally advanced rectal 
cancer, despite all the therapeutic advances [11, 168]. Whether diagnosed in advanced 
stage of primary tumor, or at any stage in the presence of positive lymph nodes, the 
standard of care treatment for rectal cancer patients is neoadjuvant chemotherapy with 
the thimidylate synthase inhibitor 5-fluorouracil (5-FU) and concomitant radiotherapy 
(chemoradiotherapy/CRT), followed by surgery [3, 169].  
It was previously described that chemotherapy, besides its cytotoxic action, may also 
induce a cellular state of irreversible proliferative arrest due to severe DNA damage, 
named therapy-induced senescence (TIS) [42, 43]. 
Initially considered to be a phenomenon typical of normal somatic cells that lost their 
ability to divide, thereby named replicative senescence, it is now known that senescence 
can also be a response mechanism triggered by several factors including oncogenic 
mutations, oxidative stress, or DNA damaging agents [47, 170].  
The effect of cellular senescence in the context of cancer is not completely understood. 
Cell senescence can play a direct role in tumor growth inhibition since it is an important 
anti-proliferative mechanism [155]. In lung and breast cancer, detection of cell 
senescence after neoadjuvant chemotherapy correlated positively with response to 
treatment [54, 171]. Also in colorectal cancer, patients with sporadic senescent cells 
detected prior to treatment had increased susceptibility to TIS and better response to 
adjuvant chemotherapy [160]. However, there is evidence that senescent cells can also 
exert deleterious effects on the tissue microenvironment [114]. The so called senescence-
associated secretory phenotype (SASP) of these cells, which includes the secretion of 
several pro-inflammatory cytokines, epithelial growth factors and tissue remodeling 
enzymes, may induce a more aggressive phenotype in non-senescent cancer cells in a 
paracrine fashion [135]. In fact, data from studies in breast, prostate, and pancreatic 
cancer, showed that senescent fibroblasts promoted tumor growth and progression by 
increasing proliferation, invasion, and inducing epithelial-to-mesenchymal transition 
(EMT) in pre-malignant and malignant cells [118, 128, 129, 131, 172]. It was further 
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shown that neoadjuvant chemotherapy-induced senescence observed in patients with 
malignant pleural mesothelioma or lung cancer was potentially associated with a poor 
outcome [158, 159]. Finally, senescent human prostate tumor cells also have a SASP, 
raising the question of broader effects of SASPs on tumor behavior [118]. Here, we 
assessed the effects of the SASP on chemoresistance to 5-FU and induction of EMT in 
vitro, and whether the coupling between cancer cell senescence and EMT induction was 
recapitulated in clinical samples from patients with rectal cancer subjected to 
neoadjuvant CRT. 
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2.3 Material and Methods 
Cell lines and human tissue specimens 
Human colon carcinoma cell lines HCT 116 and SW48, and the human rectal cancer cell 
line SW837 were obtained from the American Type Culture Collection (CCL-247, CCL235 
and CCL231, respectively). HCT 116 was cultured in McCoy’s 5A Modified Medium (Gibco) 
supplemented with 10 % fetal bovine serum (Gibco), 100 U/ml penicillin/streptomycin 
(Gibco), 2 mM L-glutamine (Gibco), and 1 % non-essential amino acids (Gibco). SW48 and 
SW837 were cultured in Dulbecco's modified Eagle's medium (DMEM; Gibco) 
supplemented with 10 % fetal bovine serum (Gibco) and 100 U/ml penicillin/streptomycin 
(Gibco). All cell lines were kept at 37C in 5 % CO2. Rectal cancer specimens (n=19) were 
collected during standard of care surgery from patients with rectal cancer who had been 
treated, or not (controls), with neoadjuvant CRT, included in OCT Compound (Sakura), 
snapshot frozen in liquid nitrogen within 30 minutes of collection, and preserved at -80C. 
This study was approved by the Ethics Commission of Hospital de Santa Maria – CHLN 
(Lisbon, Portugal), and all patients signed an informed consent. 
Induction of cell senescence  
4.0x104 HCT 116 cells were seeded in 60 mm diameter plates and continuously exposed 
to 5.0 µM 5-FU (Accord Farmacêutica Lta.) or 0.5 µM doxorubicin (Sigma-Aldrich), for 7 
days or 4 hours, respectively; media plus/minus (controls) drugs were replaced every 48 
hours. After drug removal cells were incubated with fresh medium. Conditioned media 
were collected 72 hours post-drug release (Senescence-associated secretome/SAS-
medium). Culture media conditioned by exponentially growing (non-senescent) cells 
(non-SAS-medium) were collected 72 hours post seeding. Conditioned media were stored 
at 4C and used within 48 hours of storage.  
Cellular assays 
Detection of SA-β-Gal activity in HCT 116 cells and frozen tissues was performed with the 
“Senescence Cells Histochemical Staining Kit” (Sigma-Aldrich), according to 
manufacturer’s instructions, followed by counterstaining with nuclear fast red (Sigma-
Aldrich) and visualized in a Leica DM2500 bright field microscope (Leica Microsystems). 
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Cell proliferation was assessed by alamarBlue assay and 5-bromo-2’-deoxyuridine (BrdU) 
incorporation. AlamarBlue assay (Invitrogen) was performed according to manufacturer’s 
instructions. To determine the effect of conditioned media on cell proliferation HCT 116, 
SW837 and SW48 cells were plated in 96-well plates (2.0x103; 1.0x104 and 1.0x104 
cells/well, respectively), and incubated for 24 to 72 hours in the presence of SAS-medium 
or non-SAS-medium. To test for BrdU incorporation cells induced into senescence by 5-FU 
or untreated control cells were exposed to 10 µM of BrdU for 24 hours or 1 hour, 
respectively. Cells were then fixed in 3.7 % paraformaldehyde (PFA) for 10 minutes at 
room temperature (RT); DNA was subsequently depurinated for 30 minutes in 4.0 N HCl, 
followed by a neutralization step in PBS supplemented with Tris buffer (100 mM; pH8) for 
another 30 minutes. Cells were incubated with anti-BrdU antibody (1:50; clone BMC 
9318, Roche) for 1 hour at 37°C, followed by incubation with anti-mouse Cy3 antibody 
(1:200; Jackson ImmunoResearch). Cover slips were mounted in Vecta-Shield with DAPI 
(Vector Laboratories), and visualized in a Zeiss Axiovert 200M inverted wide field 
fluorescence microscope (Carl Zeiss MicroImaging GmbH).  
Apoptosis was assessed using the Caspase-Glo® 3/7 Assay (Promega), according to 
manufacturer’s instructions. 
Immunofluorescence 
Cell lines HCT 116, SW837 and SW48 were seeded on glass cover slips (2.0x105; 9.0x105 
and 9.0x105 cells, respectively) in 60 mm diameter plates and continuously exposed to 
SAS-medium or non-SAS-medium for 72 hours. After this period the medium was 
removed, and cells were fixed with 3.7 % PFA for 10 minutes at RT. Cells were 
permeabilized with PBS/0.5 % Triton X-100 for 10 minutes and then incubated with anti-
E-cadherin antibody (1:1000; HECD-1, Invitrogen) for 1 hour at 37°C, followed by 
incubation with anti-mouse Cy3 antibody (1:200; Jackson ImmunoResearch) for 45 
minutes at 37°C. Cover slips were mounted in Vecta-Shield with DAPI (Vector 
Laboratories), and visualized in a Zeiss Axiovert 200M inverted wide field fluorescence 
microscope (Carl Zeiss MicroImaging GmbH). 
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Cytokine profiling 
Detection and semi-quantification of cytokines present in conditioned media was 
performed with the “Proteome ProfilerTM Array- Human XL Cytokine Array Kit” (R&D 
Systems) according to the manufacturer's instructions. Briefly, membranes were 
incubated with 500 µL of conditioned media corresponding to 8 mg/mL of protein, as 
determined by DC Protein Assay (Bio-Rad). Chemiluminescence detection was done in 
ChemiDoc MP (Bio-Rad). Pictures were acquired using ImageLab software (version 4.1, 
Bio-Rad) and imported to ImageJ Software (version 1.48, National Institutes of Health, 
USA) for image analysis. The mean pixel density in each dot was determined by 
subtracting the background value, and the average pixel density of duplicate spots was 
calculated.  
RNA isolation and RT-qPCR 
Cell lines HCT 116, SW837, and SW48 (3.0x104; 9.0x105 and 9.0x105 cells, respectively) 
were seeded in 60 mm diameter plates and continuously exposed to SAS-medium or non-
SAS-medium for 72 hours. RNeasy Mini kit (Qiagen) for total RNA isolation and DNase I 
(Promega) treatment were used as per manufacturer’s instructions; RNA concentration 
and purity was assessed in a NanoDrop spectrophotometer (Thermo Fisher Scientific). 
RNA (1 µg per sample) was reverse- transcribed using Superscript III First-Strand Synthesis 
System for RT-PCR (Invitrogen) as per manufacturer’s instructions with random hexamer 
primers. RNA extraction from microdissected tissues was performed using the RNeasy 
Plus Micro kit (Quiagen) according to manufacturer’s instructions. Total RNAs were 
reverse- transcribed using the RT2Nano PreAMP cDNA Synthesis kit (SABiosciences) 
according to the manufacturer’s instructions. cDNAs were amplified by semi-quantitative 
real-time PCR (qPCR) using Power SYBR Green PCR Master Mix (Applied Biosystems) and 
specific primers in a Rotor Gene 6000 (Corbett, Quiagen). Specific primers were used for 
the following genes: CDKN2A that codes for p16INK4a (PPH00207C), TYMS coding for 
thymidilate synthase (PPH01011B), IL6 and IL8 coding for IL-6 (PPH00560C) and IL-8 
(PPH00568A) (SABiosciences, Quiagen), respectively; VIM for vimentin forward 5’- 
cgaaaacaccctgcaatctt- 3’, vimentin reverse 5’-tcctggatttcctcttcgtg -3’; FN1 gene encoding 
for fibronectin, forward 5’- cagtgggagacctcgagaag- 3’, fibronectin reverse 5’- 
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tccctcggaacatcagaaac -3’; CDKN2A coding p21Waf1/Cip1 forward 5’- ctcagaggaggcgccatgt -3’, 
p21Waf1/Cip1 reverse 5’- ccattagcgcatcacagtcg -3’. The genes SNAI1, SNAI2, ZEB1 and 
GAPDH that encode for Snail, Slug, Zeb1 and GAPDH proteins, respectively were amplified 
using previously published primers [173]. Relative mRNA expression levels were 
determined using the   2-∆ct method and normalized to GAPDH housekeeping gene, using 
the mean value of three replicates.  
Invasion assay 
The cell invasion assay was performed with the 24-well BD BioCoat™ Tumor Invasion 
System (BD Biosciences), according to the manufacturer’s instructions. Briefly, HCT 116 
cells (5.0x104 cells/ml) were plated in the upper chambers and SAS-medium, or non-SAS-
medium (control), was added to the lower chambers. After 24 hours incubation at 37°C 
with 5% CO2 the cells in the membrane were stained with 4 μg/ml of Calcein-AM 
(Calbiochem, Merck Millipore) in Hank’s buffered salt solution (Gibco) at 37°C, 5% CO2 for 
1 hr, and fluorescence was quantified in a Infinite200 Multimode reader (Tecan) at 
494/517 nm (excitation/emission). 
IL-8 quantification 
IL-8 in conditioned media was quantified with the Human IL-8/CXCL8 Quantikine ELISA kit 
(R&D systems), according to manufacturer’s instructions.  
Laser microdissection  
Tumor cells were microdissected in a Laser PALM-Microbeam 4.2 microdissection system 
(Carl Zeiss MicroImaging GmbH) as previously described [174]. Sequential slides were 
obtained for the identification of senescent tumor cells (SA-β-Gal activity, as described 
above) and for laser microdissection.  
5-FU chemosensitivity assay 
For the determination of the IC50 for 5-FU, HCT 116, SW837 and SW48 cells were seeded 
in 96-well micro plates with a density of 3.0x103; 2.0x104 and 2.0x104 cells/well, 
respectively, and incubated for 72 hours (HCT 116 and SW48) or 96 hours (SW837) in 
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either SAS- or non-SAS-medium, in the presence of different concentrations of 5-FU (0.5 
to 500 µM). The alamarBlue assay was performed as described above. IC50 values were 
determined based on the analysis of dose-response curves using GraphPad Prism 
software version 5.00 for Windows (GraphPad Software).  
Flow cytometry  
DNA content was analyzed by flow cytometry. 4.0x104 HCT 116 cells were seeded in 60 
mm diameter plates and exposed to SAS-medium or non-SAS-medium for 24 hours. Cells 
were harvested by trypsinization, fixed with 1% PFA for 3 minutes at RT, and incubated 
for 10 minutes in 3.7 % PFA/HPEM buffer (Pipes 65 mM, Hepes 30 mM, MgCl2 2 mM, 
EGTA 10 mM; pH 6.9)/0.05 % Triton X-100, at RT, for fixation-permeabilization. Cells were 
washed in PBS and DNA was stained by incubation in propidium iodide (PI) solution (10 
µg/ml PI, 0.2 mg/ml RNase A, 0.05 % Triton X-100), for 40 minutes on ice, followed by 40 
minutes at 37°C. Samples were analyzed in a BD LSR Fortessa flow cytometer (Becton 
Dickinson) and cell cycle distribution was analyzed using FlowJo software (Tree Star).  
Statistical analysis 
Assays were performed in triplicate. Data were analyzed with GraphPad Prism software 
version 5.00 for Windows (GraphPad Software). Values were expressed as the mean and 
standard error mean. Differences between groups were analyzed by two-tailed unpaired 
t-test and Fisher’s exact test, as appropriate. Non-parametric Mann-Whitney test was 
used to compare two populations with independent observations. The level of statistical 
significance was set at p < 0.05. 
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2.4 Results 
2.4.1 Low-dose 5-FU induces cellular senescence in HCT 116 colorectal cancer 
cells  
To address the paracrine effects of the secretome from colorectal cancer cells on their 
non-senescent counterparts, we first induced cellular senescence by exposing HCT 116 
colorectal cancer cells to low-dose 5-FU (5.0 µM) for 7 days. At the end of this period we 
checked for the presence of senescent cells by cytochemical detection of the activity of 
Senescence-Associated β-galactosidase (SA β-gal). We observed that ~80 % of the cells 
exposed to 5-FU displayed high levels of SA-β-gal, when compared to control cells (Figure 
2.1A).  
 
 
 
 
 
 
 
Figure 2.1- Low-dose 5-FU induces cellular senescence in HCT 116 colon cancer cells.  
Detection of SA-β-Gal in HCT 116 cells not exposed to 5-FU (controls) or exposed to 5-FU (5 µM) for 7 
days. Note the increased staining for SA-β-Gal (blue signal) and enlarged size of 5-FU-treated cells. B- HCT 
116 cells not treated with 5-FU (controls) or treated with 5 µM of 5-FU for 7 days were incubated with 10 
µM BrdU for 1 hour or 24 hours, respectively, and immunostained for BrdU; cells that incorporated BrdU 
show nuclear staining (red signal; white arrows); nuclei were counterstained with DAPI (blue signal). C- 
Quantification of HCT 116 cells by alamarBlue not exposed to 5-FU (controls) or exposed to 5 µM of 5-FU 
for 7 days. Analysis of cell growth curves is consistent with ~60 % of 5-FU-treated cells being non-
proliferating. D- Quantification of apoptosis in HCT 116 cells not exposed (controls) or exposed to 5-FU (5 
µM) for 7 days. Caspase-3 and caspase-7 activities were measured by a luminescent assay (Caspase-Glo® 
3/7 Assay; cf Materials and Methods). Note that the accumulated apoptosis observed during the 
induction of senescence by 5-FU is lower than in control cultures not exposed to 5-FU. All evidences 
suggest a highly senescence enriched HCT 166 cell culture. All determinations were done in triplicate and 
data are presented as scatter plots of the mean ± SEM. *p <0.05; **p <0.01; ***p <0.001 based on an 
unpaired t-test. 
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5-FU-treated cells displayed only residual BrdU incorporation when compared to non-
treated controls (Figure 2.1B) and reduced proliferation (alamarBlue assay; p<0.05 to 
p<0.01) (Figure 2.1C), typical features of the senescent state. Measurement of caspase-3 
and -7 activities showed that apoptosis contributed little to the reduced cell numbers 
observed in HCT 116 populations exposed to low doses of 5-FU (p<0.01 to p<0.001) 
(Figure 2.1D).  
We conclude that low-dose 5-FU induced HCT 116 cells into a senescent state.  
 
2.4.2 The secretome of senescent HCT 116 cells stimulates the proliferation of 
non-senescent cells  
To test the paracrine effects of the senescence-associated secretome (SAS) we first used 
an array to characterize the cytokine profile of culture media conditioned by HCT 116 
cells induced into senescence by 5-FU, hereafter termed “SAS-medium”; controls were 
provided by culture media conditioned by exponentially growing HCT 116 cells (cf, 
Materials and Methods). This analysis revealed that SAS-media were enriched in IL-8, 
TGF-α, VEGF, cystatin C, LCN2, MIF, EMMPRIN, and uPAR (Figure 2.2A and Figure 2.2B) 
when compared to controls. Since IL-8 is a hallmark of senescence-associated secretomes 
we further quantified this cytokine by ELISA. The results confirmed a significant increase 
of IL-8 in SAS-medium (p<0.05; Fig. (Figure 2.2C)).  
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Analyses of cell viability by alamarBlue assay showed that after culturing HCT 116 cells for 
24 hours in presence of SAS or non-SAS media (controls), SAS-medium induced a 
significant increase in cell proliferation (p<0.05; (Figure 2.3)), in accordance with 
previously published data for other cell types [128, 129, 131]. To check whether this 
effect was cell-type specific we also tested the effects of SAS-media on proliferation in a 
different colon cancer cell line (SW48), and in a rectal cancer cell line (SW837). These 
results confirmed the early (at 24 h) stimulatory effect of the SAS on the proliferation of 
these cell lines (Figure 2.3).  
 
Figure 2.2- Cytokine screening array identifies secreted compounds by 5-FU-induced senescent HCT 
116 colon cancer cells. 
A- Cytokine screening incubated with either SAS- or non-SAS (controls) conditioned medium obtained 
as described in Materials and Methods; note that each of the probed cytokines is detected in duplicate 
(double-spot) in each array. B- Shown are profiles of mean spot pixel density created using ImageJ 
software. C- Quantification of IL-8 in media conditioned for 72 hours by either proliferating (non-SAS 
medium; control) or senescent (SAS-medium) HCT 116 cells. Results are expressed in pg/mL per 10
5
 
cells, and represent the mean ± SEM of triplicate experiments.  
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These data suggest that the secretome of t HCT 116 cells induced to senesce by exposure 
5-FU exerts a positive effect on the proliferation of cycling colorectal and rectal cancer 
cells. 
2.4.3 The secretome of senescent colon cancer cells promotes epithelial-to-
mesenchymal transition and increased invasiveness  
Next we investigated whether the SAS could affect the epithelial phenotype of 
proliferating colon and rectal cancer cells. We found that in contrast to incubation with 
non-SAS control medium, incubation with SAS-medium induced loss of E-cadherin 
expression, as assessed by immunofluorescence with E-cadherin-specific antibodies 
(Figure 2.4A). Moreover, our results showed a significant increase (p<0.05 to p<0.001) in 
mRNA levels of Slug, ZEB1a, Snail, fibronectin and vimentin (Figure 2.4B), all hallmarks of 
EMT, in HCT 116, SW48, and SW837 cells. Also, HCT 116 cells exposed to SAS-medium 
displayed increased invasiveness compared to control cells exposed to non-SAS 
conditioned medium (p<0.001) (Figure 2.4C). 
Figure 2.3- The secretome of senescent HCT 116 cells stimulates the proliferation of non-senescent 
cells. 
Quantification of HCT 116, SW48 and SW837 cells by alamarBlue after incubation with conditioned 
media, either non-SAS-medium (controls) or SAS-medium, for 24, 48 and 72 hours. Represented are 
ratios between values obtained after and prior to incubation with conditioned media. All 
determinations were done in triplicate and data are shown as scatter plots of the mean ± SEM. *p 
<0.05; **p <0.01 based on an unpaired t-test. 
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Figure 2.4- The secretome of senescent colon cancer cells induces epithelial-to-mesenchymal transition 
and increases invasiveness. 
A- HCT 116, SW48 and SW837 cells incubated with conditioned media, either non-SAS (control) or SAS-
enriched, for 72 hours and stained by immunofluorescence with anti-E-cadherin antibodies (red signal); 
nuclei were counterstained with DAPI (blue signal). The cellular peripheral E-cadherin signal is either lost or 
significantly reduced in cells exposed to SAS-medium. B- cells exposed to conditioned media as above (non-
SAS/control versus SAS-enriched) were analyzed by RT-qPCR for expression of EMT-related genes (Slug, 
Zeb1a, Snail, fibronectin and vimentin). Expression of these genes was normalized for GAPDH expression. C- 
the chemoattractant properties of conditioned media (non-SAS/control versus SAS-enriched medium) were 
monitored using a standard invasion assay (cf Materials and Methods). Migrating cells were scored by 
quantification of Calcein AM-associated fluorescence. All determinations were done in triplicate and data 
are given as scatter plots of the mean ± SEM. *p <0.05; **p <0.01; ***p <0.001 based on an unpaired t-test. 
 
Finally, we checked whether the observed effects of the SAS on stimulation of EMT and 
invasive behavior were dependent on the drug used to induce the SAS. To this end, we 
obtained media conditioned by HCT 116 cells that were induced into senescence by brief 
exposure to doxorubicin (0.5 µM, 4 hours); of note, this treatment resulted in a 
proportion of senescent cells (SA-β-gal staining;~ 80%) that was similar to that obtained 
after exposure to 5-FU (data not shown). Also, within the constraints of the array utilized 
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here, the cytokine profile of the SAS obtained from doxorubicin-induced senescent HCT 
116 cells was similar to that from 5-FU-induced senescent cells (Supplementary Figure 
S2.1A, S2.1B and S2.1C). Similarly, exposure to the doxorubicin-SAS also induced up-
regulation of EMT-related genes in proliferating HCT 116 cells (Supplementary Figure 
S2.1D). 
 
 
 
 
 
 
 
 
 
In sum, these data show that in presence of senescence-specific secretomes colon and 
rectal cancer cells are induced into EMT and acquire increased invasiveness. 
Supplementary Figure S2.1- Cytokine screening array and EMT induction by SAS-medium obtained 
from doxorubicin-induced senescent HCT 116 colon cancer cells. 
A-Cytokine screening arrays incubated with either SAS- or non-SAS (controls) media; SAS-media were 
conditioned by HCT 116 cells induced into senescence by doxorubicin; each of the probed cytokines is 
detected in duplicate. B- Profiles of mean spot pixel density were created using ImageJ software. C- 
SAS-medium conditioned by senescent HCT 116 cells (doxorubicin-induced senescence) is enriched in 
IL-8 relative to control (non-SAS) medium. Quantifications were performed by ELISA and are expressed 
in pg/mL per 10
5
 cells. D- expression levels of mRNAs from EMT-related genes in proliferating HCT 116 
cells incubated for 72 hours with either SAS-medium or non-SAS-medium (controls). Gene expression 
was assessed by RT-qPCR, and normalized to GAPDH expression. All determinations were done in 
triplicate and data are presented as scatter plots of the mean ± SEM. *p <0.05 based on an unpaired t-
test. 
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2.4.4 The secretome of senescent colon cancer cells increases the 
chemosensitivity to 5-FU  
Given the remarkable effects of the SAS in the modulation of phenotypes displayed by 
HCT 116 and SW48 colon cancer cells, and SW837 rectal cancer cells, we asked whether 
this might be reflected in a modified response to chemotherapeutic agents, namely 5-FU. 
To address this issue, we estimated the IC50 for 5-FU in HCT 116, SW837 and SW48 cells 
exposed for 72 hours to different concentrations of 5-FU (0.5 to 500 µM) diluted in either 
SAS-medium or non-SAS (control) medium. Analyses of cell viability by alamarBlue assay 
showed an increased chemosensitivity to 5-FU with significant reduction in IC510 values 
for each cell line (p=0.0008, p=0.045, p=0.0119, respectively) (Figure 2.5A). 
 
Figure 2.5- The secretome of senescent colon cancer cells increases the chemosensitivity of proliferating 
cells to 5-FU.  
A- Survival of HCT 116, SW837 and SW48 cells cultured in either SAS-medium or non-SAS-medium (controls) and 
exposed to different concentrations of 5-FU (0.5 to 500 µM; 72 hours for HCT 116 and SW48 cells and 96 hours for 
SW837 cells). Cell survival correlates positively with fluorescence emitted at 590 nm wavelength (alamarBlue assay; 
cf Materials and Methods). Curve fitting and IC50 determination were performed using GraphPad Prism software. 
Data were obtained in triplicate and are represented in the graph by the mean ± SEM. The IC50 dose of 5-FU 
decreased significantly in presence of the senescence-associated secretome (3.77; 8.13 and 0.29 µM) when 
compared to controls (5.72; 4.30 and 0.08 µM, respectively). B- Levels of thymidylate synthase (TS) mRNA in HCT 
116 cells treated with 2.5, 5.0 and 10.0 µM of 5-FU (72 hours) in SAS-medium or non-SAS-medium (controls). TS 
expression was measured by RT-qPCR and normalized to GAPDH expression. All determinations were done in 
triplicate and data are given as scatter plots of the mean ± SEM. *p <0.05; **p <0.01; ***p <0.001 based on an 
unpaired t-test. C- HCT 116 cells incubated with SAS-medium or non-SAS-medium (controls) for 24 and 48 hours 
were analyzed by flow cytometry after DNA staining with propidium iodide. Histograms depict relative distributions 
across the cell cycle; highlighted is the percentage of cells in S phase as determined using FlowJo software. 
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Comparable results were obtained when the SAS was induced by doxorubicin; again, in 
presence of this latter SAS-medium the IC50 for 5-FU of HCT 116 cells was reduced from 
5.72 µM (non-SAS controls) to 4.06 µM (p=0.0086) (Supplementary Figure S2.2A). 
 
 
 
 
 
 
 
 
 
 
Since the response to 5-FU critically depends on the cellular levels of thymidylate 
synthase (TS), we next tested whether the observed SAS-induced chemosensitivity to 5-
FU could be related to a lower expression of this enzyme in presence of the SAS. 
Quantitative RT-PCR data showed that exposure of HCT 116 cells to SAS-medium or 5-FU 
separately did not significantly affect the expression of TS mRNA (Figure 2.5B). However, 
the levels of this mRNA were significantly reduced when exposure to 5-FU was in 
presence of SAS-medium, but not in presence of control (non-SAS) medium (p<0.05 to 
p<0.001) (Fig. 5B). Importantly, similar results were obtained when the SAS-medium was 
obtained from doxorubicin-treated cells (p<0.05 to p<0.01) (Supplementary Figure 
S2.2B).  
These data strongly suggest that the SAS cooperates with 5-FU to reduce TS mRNA levels. 
Since the SAS significantly increased cell proliferation after 24 hours of incubation, and 
also altered sensitivity to 5-FU, an S phase-specific drug, we asked whether the SAS 
Supplementary Figure S2.2- The secretome from colon cancer cells induced into senescence by 
doxorubicin increases chemosensitivity of proliferating HCT cells to 5-FU. 
A- Exposure of HCT 116 cells to increasing doses of 5-FU (+/- SAS-medium), quantitation of cell 
proliferation by alamarBlue, curve fitting and graphical representation, and IC50 determination were as 
described previously in Figure 3. The IC50 of 5-FU decreased significantly in presence of the senescence-
associated secretome (SAS-medium; 4.06 µM) when compared to controls (5.72 µM). B- levels of 
thymidylate synthase (TS) mRNA in HCT 116 cells treated with 2.5, 5.0 and 10.0 µM of 5-FU (72 hours; 
+/- SAS-medium) as in Figure 3. TS expression was measured by RT-qPCR and normalized to GAPDH 
expression. Note the lower levels of TS-specific mRNA in cells exposed to SAS-medium. All 
determinations were done in triplicate and data are shown as scatter plots of the mean ± SEM. *p<0.05; 
**p<0.01 based on an unpaired t-test. 
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promoted any alteration in the cell cycle. To test this hypothesis, HCT 116 cells were 
cultured in either SAS-medium or else in control (non-SAS) medium for 24 hours, and 
analyzed by flow cytometry after staining the DNA with propidium iodide. This analysis 
revealed an augmented proportion of cells in S phase in presence of the SAS (26.2% 
versus 16.4% for control medium) (Figure 2.5C), consistent with the SAS accelerating cell 
division in particular the entrance into S phase. 
Taken together these results show that SASs increase the sensitivity of proliferating colon 
and rectal cancer cells to 5-FU, and strongly suggest that this stems from the SASs 
promoting a higher proportion of cells in S phase where sensitivity to 5-FU is highest. 
 
2.4.5 Neoadjuvant chemotherapy promotes emergence of senescence and EMT 
in human rectal cancers 
The previous data highlighted a relevant set of paracrine effects exerted by the SAS on 
target proliferating colon cancer cells, namely induction of EMT. We then wondered 
whether these effects might be of more broad clinical relevance, and thus observable in 
tumors from rectal cancer patients.  
We selected as model system rectal cancer samples collected at the time of surgery from 
patients that had received, or not, neoadjuvant chemoradiotherapy (CRT). Although these 
samples do not allow us to observe the impact of CRT in samples from the same patient, 
we were able to compare tumor samples from different patients prior to, and after CRT 
treatment. Therefore, patients were divided in two different groups according to 
neoadjuvant treatment (Table 2.1). These two groups were similar concerning gender 
distribution, mean of ages, pathological primary tumor classification (pT) and regional 
lymph node (RLN) involvement (p=0.3047, p=0.7553, p=0.3047 and p=0.6332, 
respectively).  
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Table 2.1- Patient and tumor characteristics 
 
Neoadjuvant CRT 
Yes (n=7) No (n=12) p value 
Male (%)  57 83 0.30471 
Age (y), median (range)  70.8 (50-84) 68.6 (43-89) 0.75532 
pT classification* (%)  
  
0.30471 
 
pT2  43 17 
 
 
pT3  57 83 
 
RLN involvement (%)  71 50 0.63321 
*Staging according to AJCC Cancer Staging Manual, 7th ed. New York, 
Springer, 2010 
1- Fisher’s exact test 2- Student’s t test  
Abbreviations: pT- pathological primary tumor; RLN- regional lymph nodes; 
CRT- chemoradiotherapy  
 
In these samples we tested whether CRT induced cellular senescence in tumor cells and, 
whether proximity to senescent cancer cells correlated with induction of EMT. To this 
end, frozen rectal cancer samples from patients who were either subjected to CRT (n=7) 
or not (controls; n=12) were sectioned, and randomly chosen clusters of cancer cells were 
laser-microdissected free of stromal components for quantitative analysis of specific 
mRNAs by RT-qPCR. 
We initially tested for expression of genes that strongly correlate with the senescent 
state, namely p21Waf1/Cip1, p16INK4a, and IL-8. Both p21Waf1/Cip1 and IL-8 were found to be 
up-regulated in the group of patients that received neoadjuvant CRT (p<0.05) (Fig. 6A) 
compared to control (non-CRT) samples, suggesting that CRT induced cellular senescence 
in these tumors. Next, we analyzed the expression of the EMT-related genes, Snail, Slug 
and vimentin in the same samples and found these genes to be significantly up-regulated 
in tumors from patients treated with neoadjuvant CRT (p<0.05) (Figure 2.6A).  
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Subsequently, in samples from patients that had received neoadjuvant CRT we obtained 
serial sections in which every other section was stained for SA-β-Gal and used to directly 
assess the presence of senescent cells in the contiguous sections (stained with cresyl 
violet). Staining for SA-β-Gal was detected in discrete regions of tumor tissue, and cancer 
cell clusters enriched for senescent cells were identified and selected (Supplementary Fig. 
S3A). These clusters, together with nearby clusters (>700 µm) in which senescent cells 
were absent (controls), were laser microdissected and used for the analysis of expression 
of p21Waf1/Cip1 and IL-8, and of the EMT-related genes Snail, Slug, and vimentin by RT-qPCR 
(Supplementary Figure S2.3B).  
Figure 2.6- Neoadjuvant chemotherapy promotes emergence of senescence and EMT in human rectal 
cancers.  
A- Total RNA was extracted from microdissected clusters of cancer cells from human rectal cancer 
samples obtained from patients that either received neoadjuvant chemo-radiotherapy (Neo.CRT+; n=7) 
or not (Neo.CRT-/controls; n=12) prior to surgery. Specified mRNAs were quantified by RT-qPCR and 
normalized to GAPDH expression. B- in rectal cancer samples from patients subjected to neoadjuvant 
chemoradiotherapy (n=4) cancer cell clusters enriched in senescent cells, and clusters locating nearby 
(>700 µm) and certified as devoid of senescent cells (controls), were laser-microdissected and used for 
quantification of specific mRNAs by RT-qPCR, as above. Note the increase in both senescence 
(p21
Waf1/Cip1
, IL-8) and EMT markers (Snail, Slug, vimentin) in tumor areas enriched for senescent cells. 
Whiskers represent the minimum and maximum across the data. *p <0.05 based on a Mann–Whitney 
U test. 
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Supplementary Figure S2.3- Representative sequential frozen sections of human rectal cancer tissue 
selected for isolation of senescent-positive and senescent-negative epithelial cell populations by 
laser microdissection.  
A- Representative sequential frozen sections of human rectal cancer tissue selected for isolation of 
senescent-positive and senescent-negative epithelial cell populations by laser microdissection. A, 
section stained for SA-β-Gal activity to identify clusters of cancer cells harboring senescent cells (blue 
staining; upper inset, left; arrows, top right) and nearby clusters devoid of SA-β-Gal staining (lower 
inset, left; bottom right); counterstaining was with nuclear fast red. B- Contiguous section stained with 
cresyl violet in which areas selected for microdissection are delineated (senescent-positive, blue lines; 
senescent-negative, already laser-ablated, red lines) Magnification, x100 (A, left) and x200 (A, right; B). 
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As expected, p21Waf1/Cip1 and IL-8 were up-regulated in tumor cell clusters enriched in 
senescent cells (Figure 2.6B). More importantly, Snail, Slug, and vimentin also showed 
increased expression in these same tumor cell clusters, indicating that senescence and 
EMT co-occurred within the same microenvironment (Figure 2.6B). It is unlikely that 
senescent cells themselves are the source of increased expression of genes related to 
EMT since this is not part of the drug-induced senescent phenotype. In fact, we found 
that expression of Snail and vimentin was significantly lower in HCT 116 cells that reached 
senescence by exposure to 5-FU compared to HCT 116 cells induced into EMT (p<0.001) 
(Supplementary Figure S2.4). 
 
 
 
Supplementary Figure S2.4- EMT-related genes are poorly expressed in senescent cells.  
Expression of vimentin and Snail were assessed by RT-qPCR in HCT 116 cells, either senescent or 
induced into EMT by exposure to SAS-enriched medium. All determinations were done in triplicate 
and data are given as scatter plots of the mean ± SEM. ***p<0.001 based on an unpaired t-test. 
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2.5 Discussion 
There is good evidence that the tumor microenvironment has a role in cancer progression 
[175]. Recently, it was shown that in rectal cancer patients receiving neoadjuvant therapy 
the patterns of gene expression of cancer-associated fibroblasts provided predictive 
power for distant recurrence and prognosis, supporting a role for the microenvironment 
in rectal cancer behavior [176]. Also, treatment of cancer patients with DNA-damaging 
agents, both in neoadjuvant and curative settings, was shown to induce epithelial cancer 
cells into accelerated forms of senescence [135]. Senescent cells derived from either non-
transformed or cancer cells are associated with senescence-specific secretomes, the SASs 
[118]. Despite the powerful paracrine effects exerted by SASs in vitro [118, 128, 129, 131, 
172], it has remained elusive to what extent senescent cancer cells present within tumors 
influence the microenvironment and, eventually, cancer progression [158-160].  
We initially interrogated the cytokine composition of the SAS from colon cancer cells (HCT 
116) induced to senesce by exposure to either 5-FU, which targets cells in S phase and 
interferes with DNA repair, or to doxorubicin, a DNA-damaging drug. We presented 
evidence that senescent colon cancer cells are able to consistently secrete several 
cytokines to high levels (eg, IL-8), irrespectively of whether senescence was induced by 5-
FU or doxorubicin. In addition, we have provided evidence that CD147, cystatin C, LCN2 
and TGF-α are also SAS-related molecules, for the first time. 
As previously described for other cell types ([118, 129, 172], in two different colon cancer 
cell lines (HCT 116 and SW48), and in one rectal cancer cell line (SW837), the paracrine 
effects of the SAS comprised increased proliferation and invasiveness, as well as induction 
of EMT, all of which correlate with aggressive cell behavior.  
Interestingly, exposure of colon and rectal cancer cells to SASs enhanced the sensitivity to 
5-FU. Chemosensitivity to 5-FU is known to depend, to a large extent, on cellular levels of 
thymidylate synthase (TS) [33]. Here, we showed that SASs further promote the reduction 
of TS levels prompted by 5-FU, thus providing a plausible explanation for the increased 
sensitivity of the three different cell lines to 5-FU in presence of SASs. Similar results 
regarding the decrease of TS expression levels could also be observed when HCT 116 cells 
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were in presence of SAS obtained from doxorubicin-treated cells, suggesting an increase 
in the sensitivity to 5-FU regardless the senescence-inducing stimuli. Since EMT has been 
correlated with increased resistance to several anti-cancer drugs [177], whether the 
effect of the SASs shown here in promoting chemosensitivity to 5-FU is restricted to this 
drug or else extensive to other cancer-specific drugs warrants further investigation. 
Moreover, prospective studies shall clarify whether the reduction observed in the IC50 
doses of 5-FU are of clinical relevance. 
Altogether, these data highlighted that the secretomes from senescent colon cancer cells 
may elicit concurrent phenomena with antagonistic prognostic value, namely EMT and 
increased invasiveness versus increased chemosensitivity. 
As mentioned, robust induction of EMT by SASs has been previously reported [118, 129], 
and was shown in this work to occur in cultured HCT 116 cancer cells in response to SASs 
derived from their senescent counterparts. Our data also showed that, in contrast to cells 
undergoing EMT, senescent cells express relatively low mRNA levels of EMT markers such 
as Snail and vimentin, thus allowing distinction between these two cellular outcomes by 
gene expression criteria. Given the consistent induction of EMT by SASs, and the known 
relevance of EMT in cancer behavior, we addressed whether the paracrine effects of 
senescent cells, via the SAS, on EMT induction seen in vitro might be recapitulated in vivo, 
in the clinical setting. Our data showed that in sections of tumors obtained from patients 
with rectal cancer the senescent cells, identified by their strong staining for SA-β-Gal, 
were present within discrete clusters of cancer cells. Laser microdissection of these 
clusters and of nearby ones devoid of senescent cells was performed and followed by RT-
qPCR analysis of senescence and EMT markers, p21Waf1/Cip1and IL-8, and Snail, Slug and 
vimentin, respectively. This showed that these genetic markers were co-expressed at 
significantly higher levels in the cancer cell clusters enriched for senescent cells relative to 
nearby ones (>700 µm) devoid of them. These data strongly suggest co-occurrence of 
senescence and EMT within the same cell clusters. They are also consistent with the 
influence of senescent cancer cells on induction of EMT being relatively short range, not 
affecting nearby niches of cancer cells. What restricts this influence remains to be 
established. 
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Tumor recurrence after preoperative chemoradioterapy followed by surgery with curative 
intent remains a major problem to successful cancer treatment affecting 15 to 20 % of 
patients diagnosed with locally advanced rectal cancer [11, 168]. Tumor regression after 
neoadjuvant chemoradioterapy has been used to evaluate treatment response and 
prognosis [21, 22]. However, results of neoadjuvant therapy can range from lack of 
effectiveness to complete pathologic remission. Clearly, the identification of novel 
predictive biomarkers of disease progression is crucial to improve adjuvant therapeutics 
and follow-up strategies. 
Future studies shall tell whether after neoadjuvant therapy for rectal cancer the presence 
of senescent cells, and EMT-related changes in their microenvironment, add prognostic 
power on cancer recurrence and patient survival. 
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3 THE IMPACT OF DRUG-INDUCED CELLULAR SENESCENCE 
IN RECTAL CANCER RELAPSE: A RETROSPECTIVE STUDY 
 
CHAPTER 3 
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3.1 Introduction  
In advanced rectal cancer (T3/T4 and/or lymph node involvement), despite the significant 
improvement in local control and radiosensitivity, achieved with neoadjuvant CRT when 
compared with adjuvant (post-surgery) treatments, disease progression often occurs [11, 
168].  
CT drugs are not always cytotoxic. In fact, tumor cells may undergo cellular senescence 
induced by CT drugs, radiation, or other DNA damaging agents [54, 170]. This is termed 
stress-induced or premature senescence, a different concept than replicative senescence 
(Chapter 1) [47, 55, 57].  
We have previously shown that cultured colon cancer cells induced to senesce by 
exposure to 5-FU (but also doxorubicin) have a specific secretome able to paracrinally 
induce EMT and increased invasiveness in neighbor proliferating tumor cells, but also able 
to increase sensitivity to 5-FU coupled to reduced expression of TS enzyme. This latter 
effect was unexpected since typically EMT connotes increased resistance to anti-cancer 
drugs. Most importantly, the effects of senescent cancer cells on EMT appear to be 
recapitulated in clinical samples from rectal cancer patients subjected to neoadjuvant 
CRT. Cellular senescence co-occurred with cells undergoing EMT in discrete niches, but 
not in nearby cancer cell niches. This provides first-hand evidence that senescent cancer 
cells influence the tumor microenvironment by promoting EMT via short range 
interactions. These findings highlight the importance of assessing cancer cell senescence 
while searching for new prognostic factors after neoadjuvant CRT in the rectal cancer 
setting. 
With the objective to establish a correlation between the presence of senescent tumor 
cells and local recurrence and distant metastasis in rectal cancer patients, we performed 
a retrospective study enrolling 35 patients diagnosed with rectal cancer and submitted to 
neoadjuvant chemotherapy. For this purpose, we first addressed the use of 
immunohistochemical (IHC) detection of SA--gal in FFPE tissues as a reliable marker to 
identify senescent cells.  
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When observed in vitro, cell senescence is generally accompanied by morphological 
changes. In particular cases, some features could vary based on the triggering factor, 
nevertheless senescent cells usually adopt a large and flat morphology, become 
multinucleated and show increased granularity. Importantly and despite some 
exceptions, these characteristics are generally not present in vivo due to architectural 
features of the tissues [53, 134, 135].  
The only validated biomarker of cellular senescence is the increased activity of the 
lysosomal protein SA-β-gal at pH 6.0, reflecting a protein overexpression and 
accumulation of the lysosomal endogenous protein content [136, 137, 178]. There are 
several studies reporting other potential senescence biomarkers (e.g. γH2AX, DEC1, DCR2, 
lipofuscin) [138, 145, 148], but the detection of SA-β-gal activity is still the only 
consensual biomarker of senescence both in vitro and in vivo [135, 179]. This fact limits 
the senescence-related studies to the use of fresh frozen tissues. Therefore, it is crucial to 
validate universal biomarkers for the detection of senescent cells in FFPE tissues. 
Although we observed a positive association between SA-β-gal activity and the IHC 
detection of SA--gal in frozen tissues, in FFPE samples the co-localization of SA--gal and 
the senescence-associated protein p16INK4a was only observed in about 20% of the 
samples. Moreover, the expression of senescence-related proteins, p16INK4a and p21WAF1, 
did not correlated with relapse (p=0.221 and p=0.357, respectively).  
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3.2 Materials and Methods  
Human samples  
This study was approved by the Ethics Commission of Hospital de Santa Maria – CHLN, 
and all patients signed an informed consent. 35 samples from patients with rectal cancer 
treated with neoadjuvant CT and RT were included. Tissue specimens collected at surgery 
were included in OCT Compound (Sakura) and snapshot frozen at -80 °C, or fixed in 
formalin and embedded in paraffin, by the Pathology Department of Hospital de Santa 
Maria, CHLN.  
Cell culture 
HCT116 human colon cancer cell line (ATCC) was cultured in McCoy’s 5A Modified 
Medium (Gibco, Invitrogen) supplemented with 10 % fetal bovine serum (Gibco), 100 
U/ml penicillin/streptomycin (Gibco), 2 mM L-glutamine (Gibco), and 1 % non essential 
amino acids (Gibco), under standard conditions. 2.0x105 cells were seeded in 60 mm 
diameter plates with cover slips and continuously exposed to 5 µM 5-FU (Accord 
Farmacêutica Lta.) for 7 days (medium was replaced by fresh medium with drug every 48 
hours) in order to induce cellular senescence. 
Immunofluorescence 
48 hours after treatment with 5 µM 5-FU, the medium was removed and cells were 
washed and fixed with 1 % formaldehyde/2 % PFA, for 2 minutes at RT, washed in PBS, 
and permeabilized with ice cold methanol for 10 minutes. Cells were washed and 
incubated with human polyclonal β-galactosidase antibody (1:50; H80, Santa Cruz 
Biotechnology), washed in PBST (0.05 % Triton x-100 in PBS) 3 x 10 minutes, and followed 
by incubation with goat anti-rabbit IgG conjugated with Alexa Fluor 488 (1:150; Molecular 
Probes). Antibodies were diluted in 0.1 % fish skin gelatin, 0.1 % sodium azide in PBS and 
incubated for 30 minutes at 37 °C. Cells were fixed in 4 % formaldehyde, washed and 
mounted in Vecta-Shield with DAPI (Vector Laboratories). Cells were visualized in a Zeiss 
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Axiovert 200M fluorescence microscope. Negative controls were obtained by omitting the 
primary antibody. 
Detection of SA-β-galactosidase activity 
Detection of SA-β-galactosidase activity was performed with the “Senescence Cells 
Histochemical Staining Kit” (Sigma-Aldrich), according to manufacturer’s instructions and 
visualized in a Leica DM2500 bright field microscope (Leica Microsystems). 
Western Blot  
For Western blot analysis, total protein extracts were prepared by lysing cells in 200 µl 2 x 
SDS loading buffer, and heating at 95 °C for 10 minutes. Samples were loaded onto a 10 % 
polyacrylamide gel and transferred to nitrocellulose membranes (Whatman). Membranes 
were blocked for 1 hour in 2.5 % skim milk in PBST, incubated for 2 hours with the 
primary antibody and for 1 hour with the secondary antibody. Signal was visualized by 
chemiluminescence using the SuperSignal West Pico Chemiluminescent HRP Substrate 
(Pierce) according to the manufacturer’s instructions. The following primary antibodies 
were used: β-galactosidase (1:200; H80, Santa Cruz Biotechnology) and β-actin (1:25,000; 
AC-15; Abcam) that was used as loading control. Anti-mouse IgG and anti-rabbit IgG 
secondary antibodies conjugated to peroxidase were purchased from Santa Cruz 
Biotechnology. 
Immunohistochemistry 
3 µm FFPE sections were deparaffinized and rehydrated. Antigen retrieval was performed 
in microwave oven, by boiling slides in 0.01 M sodium citrate buffer pH 6.0 (Sigma-
Aldrich) for 10 minutes, 20 minutes, or in Tris-EDTA pH 9.0 for 30 minutes, for p21WAF1 
(EA10, Millipore), β-gal or Ki-67 (MIB1, Dako) immunodetection, respectively. For p21WAF1 
immunostaining, slides were kept in antigen retrieval solution allowing cooling for 20 
minutes and cells were permeabilized with 0.05% Triton x-100 for 10 minutes with gentle 
agitation. 5 µm cryostat sections were fixed in ice cold acetone for 2 minutes, and washed 
2 x 2 minutes in wash buffer (0.005 % Triton x-100 in PBS). Endogenous peroxidase was 
blocked by incubation in 1.5 % or 0.3 % hydrogen peroxide in methanol (FFPE or frozen 
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sections, respectively) for 10 minutes. Total protein was blocked with Protein Block 
reagent (Dako) for 15 minutes. Primary antibodies were diluted in Antibody dilution 
solution (Dako) and incubated for: anti- p21WAF1, 1 hour at RT (1:50) followed by two 
washes of 5 minutes in wash buffer, for anti-β-gal, 1 hour at RT (1:50) followed by 15 
minutes in wash buffer with gentle agitation for FFPE sections, or 1 hour at 4 °C (1:100) 
followed by 5 minutes in wash buffer for frozen sections; and anti-Ki-67, 30 minutes at RT 
(1:100) followed by 2 x 3 minutes in wash buffer for FFPE sections. Detection was 
performed with EnVision™ Dual Link HRP Rabbit/Mouse (Dako) for 30 minutes at RT. 
Slides were rinsed in wash buffer and incubated with 3,3’-diaminobenzidine (Dako) for 5 
minutes p16INK4a immunodetection (CINtec® Histology Kit) was performed according to 
the manufacturer’s instructions. All sections were counterstained with hematoxylin and 
visualized in a Leica DM2500 bright field microscope (Leica Microsystems).  
Tissue analysis was performed by an independent Pathologist. The German 
Immunohistochemical Scoring System was applied for p16INK4a. Tissues were evaluated for 
the intensity of the nucleic and cytoplasmic staining (0- no staining, 1-weak staining, 2- 
moderate staining and 3- strong staining) and the proportion of stained cells (0 < 1 %, 1- 
1– 25 %, 2- 26–50%, 3- 51–75% and 4- 76– 100%). The final score was determined by 
multiplying the intensity score with the proportion score, giving a minimum score of 0 
and a maximum score of 12. For p21WAF1 the obtained score represents the percentage of 
positive cells: 0 < 1%, 1- 1-5% and 2- > 5%. 
Statistical Analysis 
Logistic regression analysis was performed in IBM SPSS Statistics software. The Student’s t 
test, the Chi square test and the Fisher’s exact test were used throughout as appropriate. 
The level of statistical significance was set at p < 0.05. 
68 
 
3.3 Results and Discussion  
Senescence-related studies are limited to the use of fresh frozen material and the 
cytochemical detection of SA-β-gal activity at pH 6.0. To retrospectively study archived 
FFPE samples of human rectal cancer, we first addressed the possibility to use the 
detection of β-galactosidase by IHC to identify senescent cells in this cohort. 
3.3.1 β-galactosidase is increased in 5-FU-induced HCT 116 senescent cells  
We first established an in vitro model of senescence using HCT 116 colorectal cancer cells. 
In accordance to what we previously described (Chapter 2) after a continuous exposure 
to 5.0 µm 5-FU for 7 days, SA-β-gal-positive blue cells with the typical enlarged 
senescence-like morphology were observed (Figure 3.1A). With this model we obtained 
approximately 80% senescence-enriched cell cultures.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1- β-galactosidase expression is increased in senescent HCT116 cells. 
Histochemical staining for the enzymatic activity of SA-β-Gal in HCT116 cells treated with 5 µM of 5-FU 
A- Black arrow indicates blue staining resulting from SA-β-gal enzymatic activity in typical enlarged 
senescence-like cells. β-gal (green) was detected by immunofluorescence B- Arrows point to 
perinuclear β-gal overexpression in enlarged and flattened senescent cells. Open arrowheads indicate 
lack of perinuclear β-gal overexpression in non-senescent cells. Negative control was obtained by 
omitting the anti-β-gal antibody. Nuclei were stained with DAPI (blue). β-gal expression was analysed 
by Western Blot C- β-actin was used as loading control.  
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It was previously described that the increase in SA--gal activity at pH 6.0 also reflects an 
increase in the lysosomal content of this protein, due to the gain of cellular volume, 
typical of the senescent phenotype [137, 178]. Therefore we hypothesized that β-gal 
overexpression could be used to identify senescent cells namely when the detection of 
enzymatic activity is not possible. To address if we could detect β-gal overexpression in 
senescent cells, we started by visualizing β-gal overexpression by immunofluorescence 
(IF). In fact we observed strong perinuclear staining in all the enlarged and flattened cells 
(Figure 3.1B).The increase in β-gal protein was confirmed by Western blot (Figure 3.1C) 
and was consistent with previously reported results [137].  
Based on these results we further analyzed whether we could detect β-gal overexpression 
by IHC in FFPE tissues, and especially if it could be used to identify senescent cells, in the 
absence of distinctive morphologic features. 
3.3.2 β-galactosidase immunostaining associates with SA-β-gal activity in frozen 
rectal tumors 
Using fresh frozen samples of human rectal cancers from patients treated with 
neoadjuvant CRT, we could detect SA-β-gal activity in the tumor glands (Figure 3.2A). We 
also observed cytoplasmatic β-gal staining by IHC in the same areas of sequential sides 
(Figure 3.2B).  
 
 
 
 
 
 
 
 
Figure 3.2- SA-β-gal activity co-localizes with β-galactosidase expression in frozen rectal cancer 
samples. 
Sequential tissue sections from a rectal cancer specimen were used for detection of A- enzymatic 
activity of SA-β-gal at pH6.0 and B- β-gal by IHC. 
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Based on this results, we hypothesized that detection of β-gal by IHC could be a potential 
marker of cellular senescence. Therefore, we proceed by optimizing a protocol for IHC 
detection of β-gal in FFPE tissues of rectal cancer. 
3.3.3 Positive β-gal/p16INK4a cells are heterogeneously found among rectal 
cancer tissue specimens  
We observed specific cytoplasmatic β-gal staining in tumor cells from FFPE tissues of 
rectal cancer (n=35) (Figure 3.3A). 
To further characterize the specificity of the immune signal, next we assessed the co-
localization of β-gal with p16INK4a, a Cdk inhibitor previously reported as a marker of 
senescence [143].  
By analyzing sequential slides we observed a co-localization between β-gal and p16INK4a 
(Figure 3.3B), suggesting that β-gal and p16INK4a positive cells are in fact senescent cells. 
To reinforce this data, we further confirmed the unproliferative state of β-gal/p16INK4a 
positive cells, that were negative for Ki-67 immunostaining (Figure 3.3C). Moreover, 
positive β-gal/p16INK4a and negative Ki-67 cells, were shown to be non-apoptotic cells by 
TUNEL assay (data not shown).  
 
 
 
However, specific co-localization between β-gal and p16INK4a was only observed in 20% 
(7/35) of the cases. 63% of the samples showed a partial co-localization of β-gal and 
p16INK4a, 10% of the samples were β-gal positive / p16INK4a negative, 3% were p16INK4a 
positive / β-gal negative, and 3% of the samples were negative for both markers.  
Figure 3.3- β-galactosidase co-localizes with p16INK4a in FFPE tissues. 
Sequential FFPE sections of human rectal cancer were stained by IHC for A- β-gal; B- p16INK4a, and C- 
Ki-67. Arrows indicate co-localization between expression of β-galactosidase and p16INK4a. Cells 
negative for Ki-67 are indicated by arrowheads.  
71 
 
In conclusion, the immunodetection of β-gal/p16INK4a was shown to be inconsistent 
among the samples tested.  
Moreover, it is described that from the four members of INK4 family, p16INK4a is 
inactivated in a large proportion (>30%) of all human tumors [180], leading to false 
interpretations of the results in cases highly or poorly stained for p16INK4a, respectively. 
This can account for the lack of co-localization with β-gal positive cells in some cases. 
We also observed that variable fixation periods during sample processing, can affect the 
immunodetection of β-gal, suggesting that β-gal IHC staining must be optimized according 
to the sample processing protocol. Fixation time was not uniform across our cohort, 
which may have contributed to observation of p16INK4a positive / β-gal negative cells. 
The potential biases in β-gal IHC staining lead us to decide that it is not, so far, a suitable 
marker for senescence in FFPE studies.  
In the absence of an unambiguous single marker, it is recommend the use of at least two 
senescence-related proteins for senescence identification [53]. Thus, to further analyze 
the potential correlation between senescence and relapse in human rectal cancers we 
decided to use two independent markers, p16INK4a and p21WAF1. Although p16INK4a is not a 
universal marker of senescence it was previously shown to correlate with senescence 
both in vitro and in vivo. p21WAF1, other Cdk inhibitor, also proved to be a viable marker in 
specific contexts like senescent hepatocytes from non-alcohol-related fatty liver disease 
[135, 144].  
3.3.4 There is no correlation between senescence markers p16INK4a or p21WAF1 
and cancer relapse  
To address if cellular senescence could be related with poor clinical outcome, we 
performed a retrospective analysis in a cohort of patients diagnosed with rectal cancer, 
positive regional lymph nodes (pN1-2) and treated with neoadjuvant CRT (n=35). Patients 
were stratified in two groups according to disease relapse or not at least three years after 
the diagnosis (n=23 and n=12, respectively) (Table 3.1). There were no differences 
regarding major clinicopathologic parameters that could influence the risk of relapse. 
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Table 3.1- Patient and tumor characteristics and treatment factors (n=35) 
Characteristics 
 
With relapse Without relapse p value  
 
No. of patients (%) 23 (66) 12 (34)  
Age 
   
 
 
Median 61 66 0.3131
*
 
 
Range 33-77 55-83  
Sex (%) 
   
 
 
Male 14 (61) 8 (67) 1.0000
£
 
pT classification (%) 
   
 
 
pT1 ----- 2 (17) 0.4210
#
 
 
pT2 7 (30) 3 (25)  
 
pT3 13 (57) 6 (50)  
 
pT4 3 (13) 1 (8)  
Clinical stage (%) 
   
 
 
IIIA 4 (17) 5 (42) 0.7768
#
 
 
IIIB 14 (61) 6 (50)  
 
IIIC 5 (22) 1 (8)  
K-ras status (%) 
   
 
 
Mutated 6 (26) 5 (42) 0.4506
£
 
 
Wild type 17 (74) 7 (58) 
Adjuvant chemotherapy (%) 
  
 
 
Fluoropyrimidine 
only 
5 (22) 4 (33,3) 0.5572
#
 
 
Oxaliplatin-based 12 (52) 4 (33,3)  
 
Other 6 (26) 4 (33,3)  
Time to progression (months) 
  
 
 
Median 20 -----  
 
Range 3-35 -----  
Follow-up (months) 
  
 
 
Median ----- 58  
 
Range ----- 35-93  
Positive IHC (%) 
  
 
 
p16
INK4a
 18 (78) 12 (100) 0.5673
£
 
 
p21
WAF1
 17 (74) 7 (64)  
*
Student’s t test; £Fisher’s exact test; #Chi square test 
 
Next we analyzed by IHC the expression of p16INK4a and p21WAF1. The expression of 
p21WAF1 was detected in a reduced number of cells per tumor sample and was not 
observed in all samples, while p16INK4a was broadly stained in 77 % of the analyzed 
samples. Data from logistic regression analysis did not showed a significant correlation 
between p16INK4a (p=0.221) or p21WAF1 (p=0.357) and relapse (Table 3.2). 
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Table 3.2- Logistic regression analysis to correlate independently p16INK4a and p21WAF1 
immunohistochemical scores with relapse (n=35). 
 
Odds ratio 95% CI p value 
p16
INK4a
  0.885 0.727 1.077 0.222 
p21
WAF1
  0.552 0.156 1.953 0.357 
We believe that two important factors may have impaired an accurate analysis, justifying 
further research. First, in this retrospective study the number of enrolled patients was 
small (n=35). This study only enrolled patients diagnosed prior to 2009 (with at least three 
years of follow-up), and about 20 new patients with rectal cancer are admitted annually 
at the Oncology Department of HSM, for who the standard of care treatment includes 
neoadjuvant CRT. Secondly, as above described, the lack of a universal marker or protocol 
to identify senescent cells in FFPE samples persists. Finally, we cannot exclude that the 
paradoxical effects of SAS compounds, as observed in our previous experiences, could be 
responsible for the lack of correlation between the TIS markers and the risk of relapse. 
The possibility to identify senescent cells in fixed tissues could represent an important 
tool to investigate the role of senescence not only in neoplastic diseases but also in 
chronic inflammation and age-related pathologies. Since the particular morphological and 
biochemical characteristics observed in senescent cells in vitro are not distinguishable in 
rectal cancer archived samples, our efforts have been towards the validation of a method 
applicable to FFPE tissues. Our results suggest that the detection of β-gal protein 
overexpression by IHC could be a useful method to identify senescent cells in FFPE 
tissues, although requiring sample-specific optimization of the IHC protocol.  
In summary, the search for a new universal marker of senescence is still a major goal as it 
is the clear determination of senescence’s role in CRC patient´s outcome. For this purpose 
the cohort of patients is being enlarged in order to obtain a more representative group of 
samples with higher statistical power.  
Given the clinical benefit that can be achieved with neoadjuvant chemotherapy, it will be 
important to determine the effects of senescence on tumor progression, which may lead 
to modulate or even to create new therapeutic strategies. 
74 
 
75 
 
 
 
 
 
 
 
 
 
4 GENERAL DISCUSSION 
 
 
 
 
 
 
 
CHAPTER 4 
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4.1 General discussion  
The work presented in this thesis was performed in the Clinical and Translational 
Oncology Research Unit (Luis Costa Lab), in strict collaboration with the Oncology Division 
from Hospital de Santa Maria-CHLN. 
Translational science is based on real medical questions and needs (“from the bed-side to 
the bench”) and the ultimate goal is to apply the acquired knowledge in the finding of 
new perspectives to deal with a disease that affects not only the patients’ group study, 
but thousands of people worldwide (“from the bench to the bed-side”). 
The main goal of this work was to determine the effects of TIS in rectal cancer.  
Globally, the results obtained during this research project have provided a deeper 
knowledge about the possible non-cytotoxic parallel effects of chemotherapy in rectal 
cancer patients. Data is presented and discussed in Chapters 2 and 3. In this chapter the 
full implications of our work will be described, to a better understanding of tumor biology 
and in particular of tumor response to chemotherapy. 
Tumor relapse, local or distant, occurs due to treatment resistance or under prognosis, 
and is still the leading cause of death of cancer patients. Therefore, development of 
effective and personalized therapy is one of the main challenges in medicine in order to 
improve disease free survival of cancer patients. 
In advanced rectal cancer, relapse rates remains as high as 15 to 20%, despite the efforts 
to improve local control and distant recurrence, which suggests that residual malignant 
cells either in the site of primary tumor or already in circulation may require more 
effective and additional therapeutics.  
Pathological staging following neoadjuvant CRT and surgery is the most important 
prognostic factor to predict relapse in rectal cancer, and is based on tumor extension 
through the rectal wall and spread to the regional lymph nodes [20]. More recently, the 
use of TRG has demonstrated the relevance of the presence of viable tumor cells after 
CRT as a prognostic factor [22]. However, it is still not possible to identify the patients 
that will have resistance to CT, and complete or partial tumor response to neoadjuvant 
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treatment [181]. Therefore, the identification of novel predictive biomarkers of response 
to treatment and predictive of relapse is extremely important in order to improve 
individualized therapeutic strategies and increase cure rates.  
Currently, cellular senescence is considered an important tumor suppressor mechanism 
by limiting uncontrolled proliferation of cells and preventing neoplastic transformation 
[116]. However, it was previously shown that senescent cells acquire a SASP, a secretome 
largely composed by inflammatory cytokines/chemokines, growth factors and 
extracellular-matrix-remodeling proteins, secreted to the external environment that may 
promote tumor progression [129]. Throughout the course of the present work, we 
established an in vitro model of TIS in CRC and also analyzed human samples from rectal 
cancer, to address the effect of senescent tumor cells, rather than associated stromal 
cells, in tumor behavior.  
Presently, 5-FU is still widely used to treat different cancers, including breast and CRC, 
and is the main CT drug recommended in the neoadjuvant setting for treatment of 
advanced rectal adenocarcinoma [3, 11].  
Pharmacokinetic profile of the continuous Iv infusion of 5-FU is well established [39-41, 
182], and Cpss values range from 0.39 µM to 66.3 µM, probably due to different 
metabolic rates [40, 41]. In this work we established an in vitro model of TIS by mimicking 
the effects of clinically relevant concentrations of 5-FU. In this context, HCT 116 colon 
cancer cells were continuously exposed to a low concentration of 5-FU, specifically 5.0 
µM, for seven days (Figure 2.1). Our goal was to determine the effect of such low 
concentrations in cellular outcome, since standard CT regimens, besides cell death, can 
induce TIS [42, 43, 54].  
While senescence’s importance is highly recognized, there are still many key questions to 
be answered. Could the imbalance of several pro-inflammatory cytokines, epithelial 
growth factors and tissue remodeling enzymes secreted by senescent tumor cells 
interfere with tumor cell capacity to become undifferentiated, survive and proliferate? Or 
could instead sensitize tumor cells to chemotherapy, improving drug response? Could 
senescence be related with cancer relapse?  
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We hypothesized that the pro-tumorigenic effect of senescence could be related with the 
high relapse rates in rectal cancer.  
Using a cytokine array, we first analyzed the cytokine profile of the CMs obtained either 
from HCT 116 senescent or non-senescent cells (control). The results showed the 
exclusive presence of several cytokines like IL-8, MIF, VEGF, and uPAR in the CM from 
senescent cells. Moreover, four cytokines (e.g. EMMPRIN, cystatin C, LCN2 and TGF-α) 
were described as part of the SASP for the first time (Figure 2.2A and Figure 2.2B).  
Afterwards we quantified IL8 from both collected CMs and the results showed a 
significant increase of IL8 in CM from HCT 116 senescent cells in accordance with cytokine 
array results. Therefore we named it SAS-medium (Figure 2.2C), and used it in 
subsequent analysis. 
The functional effects of SAS-mediums from different sources have been previously 
studied, becoming evident that senescent fibroblasts acquired a powerful secretome 
capable of promoting tumorigenesis [118, 128-131, 172]. Recently, some reports shed 
some light about the effects of different SAS in distinct neoplastic contexts [133, 183, 
184].  
Considering that the overexpression of the cytokines found in SAS-medium has been 
implicated in CRC, contributing to cancer progression [185-187], we subsequently 
investigated the effects of the SAS-medium from TIS tumor cells in non-senescent tumor 
cells of three different CRC cell lines (two colon cancer cell lines- HCT 116 and SW48, and 
one cell line from rectal cancer- SW837).  
We provide significant in vitro evidences that the SAS-medium stimulated cells to 
proliferate (Figure 2.3), induced a loss of E-cadherin, a specific epithelial cell marker, 
significantly increased the expression of EMT-associated genes like Snail, Slug, ZEB1A, 
vimentin and fibronectin (Figure 2.4A and Figure 2.4B), and significantly increased cell 
invasion (Figure 2.4C).  
During EMT, cells undergo through the process of dedifferentiation, losing the epithelial 
markers and apical-basal cell polarity leading to shape alterations. The gain of 
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mesenchyme-like phenotype comprises actin cytoskeleton reorganization and cytokeratin 
intermediate filaments are replaced by vimentin intermediate filaments. Thus, cells 
change from a cuboidal to a spindle shape, promoting cell migration and invasion. 
Therefore, the dedifferentiation of cells during EMT is considered a key process, in tumor 
progression, facilitating tumor cell dissemination and metastasis [177, 188].  
Therefore, our data suggests that SAS components from epithelial CRC cells contributes to 
an acquisition of mesenchymal features and, by this mean, to a more aggressive and 
invasive phenotype.  
Next, we tested SAS-medium’s effects in cellular response to 5-FU. We showed for the 
first time that SAS increased chemosensitivity to 5-FU by reducing 5-FU IC50 values in all 
tested cell lines (Figure 2.5A). An ongoing prospective study which details will be 
provided further ahead in this chapter, will allow us to clarify whether the reduced IC50 
values are clinically relevant or not.  
It was previously shown that in CRC, expression of TS enzyme was correlated with the 
response to 5-FU-based therapies with improved responses in patients with low TS 
expression [33]. Therefore, we addressed the TS expression and interestingly we found a 
significant decrease in TS expression in cells incubated with SAS-medium (Figure 2.5B). 
Additional data from cell cycle analysis showed an increased number of cells accumulated 
in S-phase when incubated with SAS-medium (Figure 2.5C).  
These results lead us to hypothesize that SAS-medium also sensitizes tumor cells to 
chemotherapy, improving drug response.  
Furthermore, we obtained similar results using CM from doxorubicin-induced senescent 
HCT 116 cells, leading us to conclude that the observed effects were independent of the 
drug used to induce senescence (Supplementary Figure S2.1, Supplementary Figure S2.2 
and Supplementary Figure S2.3).  
Subsequently we questioned about the physiopathological relevance of the above 
described results. To address this we used frozen rectal cancer specimens, from patients 
treated or not with neoadjuvant CRT, collected during standard of care surgery. Next we 
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randomly selected and isolated clusters of tumor cells free of stromal components, by 
laser capture microdissection. We analyzed the isolated tumor cells for specific mRNAs 
and importantly we verified that the expression of the senescence-related gene 
p21Waf1/Cip1, of the SAS component IL8, and EMT-related genes like Snail, Slug and 
vimentin was increased in samples from patients that were submitted to treatment 
before surgery (Figure 2.6A).  
Moreover, we specifically isolated and compared the expression of these genes in clusters 
of tumor cells enriched in senescent cells with their expression in tumor cells located far 
from the senescent cells. Our results provide clear evidence about the local effects of SAS 
from senescent tumor cells, since the expression of IL-8 and EMT markers decreased in 
the tumor cells that distance 700 µm from senescent cells (Figure 2.6B).  
Therefore we hypothesize a dual effect of SAS from senescent tumor cells. If on one hand 
we showed that the secretome of senescent tumor cells promote more aggressive 
phenotypes by inducing dedifferentiation of epithelial transformed and proximal tumor 
cells with potentially implications in cancer relapse, on the other hand, we showed 
evidences of an anti-tumor effect by sensitizing cells to 5-FU treatment and therefore 
improving drug response.  
Paradoxical effects of SAS compounds have been described in the past. If on one hand the 
SAS favors malignancy in neighboring cells, on the other hand, it may reinforce growth 
arrest and protect against cancer by activating the immune response, inducing the 
clearance of damaged and pre-neoplastic cells [125, 126, 128].  
In addition, some authors support the theory that senescence may have evolved as an 
example of antagonistic pleiotropy, since it provides beneficial traits during the 
reproductive age of an individual (tumor suppression via growth arrest), but causes 
deleterious effects later on in life (aging and cancer via SAS) [116]. 
However, this is the first study providing evidence that senescent cancer cells influence 
the tumor microenvironment by promoting EMT via short range interactions in human 
rectal cancer samples. Moreover, we report the first evidences of increased 
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chemosensitivity in cells from a CRC cell line when incubated with SAS in combination 
with 5-FU.  
Distinct quantitative and qualitative differences in SAS were already described [118]. As 
expected, the effects of senescent cells within the tumor microenvironment are complex 
and highly dependent on physiological context demonstrating how complex and 
heterogeneous the senescent biological program can be. Therefore, we have no doubt 
that important information could be obtained with the complete screening of SAS-
medium composition. This information would be critical to identify potential new 
therapeutic targets and to develop new strategies aiming the inhibition of the cancer- 
promoting components of the SAS. 
Based on the obtained results, we could not determine whether cellular senescence may 
indeed contribute to patient outcome after anticancer therapy. The phenomenon of 
drug-inducible senescence in tumors treated with neoadjuvant chemotherapy requires 
further research in order to determine its significance in patient’s outcome. We 
hypothesized that senescence may specifically correlate with rectal cancer relapse. 
Therefore we performed a retrospective study enrolling 35 patients diagnosed with 
advanced rectal cancer, treated with neoadjuvant CRT, and with clinical follow-up of at 
least three years after the diagnosis in order to investigate a possible correlation between 
senescence and clinical outcome of rectal cancer patients. Patients were stratified in two 
groups according to stable disease or relapse (Table 3.1).  
We then evaluated the presence of senescent cells in tumor specimens. To address the 
detection of senescent cells in FFPE tissues we first attempt to validate β-galactosidase 
detection by IHC as a new method for the identification of senescent cells applicable to 
FFPE tissues (Chapter 3).  
However, despite the promising preliminary results obtained in frozen tissues, where we 
showed a clear association between SA-β-gal activity and the immunohistochemical 
detection of -gal, in FFPE tissues the results were inconsistent (Figure 3.2 and Figure 
3.3). In the absence of one ‘gold standard’ marker, and despite the fact that these are not 
universal markers of senescence [180], we selected the expression of Cdks inhibitors 
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p16INK4a and p21Waf1/Cip1, whose increased expression mediates cell cycle arrest in 
senescence. Moreover, these two proteins were already used to identify senescent cells 
in different contexts [135, 138, 144, 159].  
The expression of these two senescence-associated markers was not uniform across 
tumor samples. In fact, p21WAF1 was detected in a small proportion of tumor cells versus 
the entire tumor cell population, while p16INK4a was broadly detected in the tissue 
sections of majority of samples. We could not find a significant correlation between the 
scores found by IHC for p16INK4a or p21WAF1 and cancer relapse. 
These results are, therefore, inconclusive. Either due to the small number of patients 
enrolled for this study, or to the lack of a reliable marker of senescence, we believe this 
study should be enlarged and repeated with other markers of senescence. 
Over the past few years cellular senescence has been clearly identified in a variety of in 
vitro cancer models. Consistently, evidences show that senescence response can be 
invoked by a wide spectrum of agents in specific conditions, and in fact contribute to 
treatment outcome [54, 156]. However, due to heterogenic findings, the presence of 
senescence often failed to accurately predict the clinical outcome of cancer patients.  
Breast cancer cells in a mouse model of doxorubicin-induced senescence showed to be 
highly resistant to apoptotic stimuli and to likely contribute to cancer relapse through its 
autocrine/paracrine activity [157]. Furthermore, senescence in human samples from 
patients treated with neoadjuvant CT is correlated with low OS and shorter PFS (p= 
0.0098 and p= 0.022, respectively) in patients with malignant pleural mesothelioma and 
with a decrease in OS (p= 0.04) in cases of non-small cell lung carcinoma. On the contrary 
CRC patients with senescent cells detected previous treatment tend to increase TIS 
susceptibility and, according to the authors, have better chemotherapy responses [160]. 
Conventional anti-cancer CT may fail due to inaccessibility of tumors, cellular 
heterogeneity, or even resistance to treatment. While increasing drug concentrations 
could overcome the low chemosensitivity, its clinical applicability is limited due to 
concomitant toxicity [189].  
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An alternative strategy to improve the response to cancer therapeutics is the induction of 
cytostasis, which permanently arrests the proliferative capacity of cells without inducing 
cell death per se. In this context, the induction of tumoral senescence could represent a 
different approach in treatment of neoplastic diseases. 
TIS could provide an effective and persistent inhibition of the tumor growth in both early 
and late-stage cancers rather than causing tumor regression. In addition, induction of 
senescence implies the use of lower drug concentrations, limiting toxic side effects. In 
theory, senescence induction could provide equivalent or prolonged survival with less 
severe side effects related to toxicity and may provide a more realistic goal for the 
chronic management of some cancers [42, 190]. 
Again, there are controversial opinions since senescent cells remain viable and 
metabolically active, acquiring a new transcriptional profile – SASP. We demonstrated 
that the SAS may inhibit the growth of the surrounding cells or, alternatively, may be 
implicated in growth and invasion promoting effects, increasing the risk of cancer relapse. 
For those reasons, until now there are no evidences of pro-senescence cancer therapies 
that exploit SAS components at either experimental or preclinical stage [191]. 
While therapies that induce cellular senescence can be a potential strategy to fight 
cancer, the accumulation of senescent cells on aging tissues may fuel the development of 
late life cancer. Studies in aging have suggested an association between age-related 
senescence and the promotion of chronic inflammation and carcinogenesis in 
surrounding tissues [192]. In this context, some authors are pointing out the beneficial 
aspects of quantitative elimination of senescent cells as therapeutic priority, either 
through the immune system or through biological or chemical approaches. A recently 
published report unveiled the hypercatabolic nature of TIS, an approach therapeutically 
exploitable by synthetic lethal metabolic targeting where it was shown that blocking 
metabolic demands of TIS induction, like glucose, led to selective elimination of senescent 
cells, prompted tumor regression and improved treatment outcomes [193].  
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The induction of senescence as a new approach in cancer therapy requires intensive 
research and the clear identification of the pathways that regulate senescence and of the 
specific senescence-inducing agents.  
To conclude, the results obtained in this work suggest that neoadjuvant therapy may not 
only exert its effectiveness by downstaging or reducing tumor cell proliferation, but also 
by qualitatively altering the phenotype of cancer cells and ultimately increasing drug 
perception of the remaining apoptosis resistant cells. Given the additional clinical benefit 
that can be achieved by neoadjuvant CT in rectal cancer, long-term prospective data on 
the prognostic impact of TIS is still missing.  
For that reason, during the course of this project, we started to prospectively collect 
serum samples from patients treated with intravenous infusion of 5-FU. So far we have a 
total of 75 serum samples corresponding to 25 patients with rectal cancer treated with 
neoadjuvant CRT. Blood samples were collected at baseline, i.e., before treatment 
initiation, after 48 hours of continuous drug administration and in the last day of 
treatment. It is our main goal to determine the serum concentrations of 5-FU in the 
different time points and correlate it with tumor cells fate on the surgical specimen of the 
same patient. These results will allow the stratification of patients based in the ability to 
produce tumor cell senescence following chemotherapy in neoadjuvant settings and 
improve patient-oriented therapy outcome. 
 
Final remarks 
The findings compiled in this thesis can impact the current scenario of rectal cancer 
treatment strategies.  
TIS may be a predictive factor for treatment outcome and the either pre-existing or CT- 
induced senescence should be addressed in order to improve and personalize cancer 
treatments.  
This work focused in rectal cancer and it only became possible not only due to the truly 
commitment of the patients by giving their consent to study their biological samples 
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(blood, biopsies and surgical specimens), but also by the collaboration between basic 
scientists, oncologists, surgeons, pathologists and even nurses and technicians. Through 
our work and through the communication bridge that we established everyday between 
basic science researchers and health care professionals, we expected to give our 
contribution for the translational cancer research field.  
We have summarized the evidences indicating a dual role of SAS from TIS tumor cells in 
non-senescent tumor cells both in CRC cell lines and in samples from CT-treated patients 
with advanced rectal cancer. We propose that despite SAS form senescent cancer cells 
influence the tumor microenvironment by promoting EMT in a specific range of action, 
favoring tumor progression, it also sensitizes tumor cells to chemotherapy, improving 
drug response. We also suggest further in vivo studies, not only increasing the number of 
samples in the clinicopathologic study, but also additional prospective data that will shed 
light if drug-inducible senescence might even act as the essential prognostic factor in 
determining tumor control versus relapse. Future studies, aimed at providing a greater 
understanding of SAS-medium composition of epithelial CRC cells to further dissect 
underlying signaling cascades with particular focus for the secreted factors involved in the 
chemosensitivity effect are required.  
Some barriers still remain, including the identification of more reliable markers of 
senescence and continued investigations of the biological implications of senescence in 
the clinical outcome of patients.  
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